Page last updated: 2024-12-06

atracurium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Atracurium besylate is a non-depolarizing neuromuscular blocking agent used for muscle relaxation during surgery and mechanical ventilation. It is a synthetic, bis-quaternary ammonium compound derived from the naturally occurring alkaloid, tubocurarine. Atracurium's synthesis involves complex chemical reactions, starting with the preparation of intermediates followed by their coupling to form the final molecule. It works by competitively binding to acetylcholine receptors at the neuromuscular junction, blocking the transmission of nerve impulses to muscles, resulting in muscle paralysis. Atracurium is known for its rapid onset of action and short duration, due to its unique property of undergoing degradation in the body through Hoffman elimination, a process that is independent of hepatic metabolism. This makes it suitable for use in patients with liver disease, as it does not accumulate in the body. The importance of atracurium lies in its ability to provide muscle relaxation during surgery and mechanical ventilation, facilitating procedures like intubation and surgery. Its short duration of action allows for faster recovery and reduces the need for prolonged mechanical ventilation. Atracurium's unique properties and clinical advantages make it a widely studied drug. Ongoing research explores its potential applications in various clinical scenarios, including the treatment of spasticity and muscle spasms, and its use in combination with other drugs to enhance anesthetic effects.'

Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47319
CHEMBL ID1360
CHEBI ID2914
SCHEMBL ID7773510
MeSH IDM0001922

Synonyms (43)

Synonym
PRESTWICK3_000005
BSPBIO_000009
isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl))-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-
brn 1523633
isoquinolinium, 1,2,3,4-tetrahydro-2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-2-methyl-
isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-
BPBIO1_000011
PRESTWICK2_000005
AB00514743
64228-79-1
C07548
atracurium
SPBIO_001930
PRESTWICK1_000005
HMS2090I21
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
CHEBI:2914 ,
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate
CHEMBL1360 ,
atracurium cation
atracurium ion
bdbm92478
unii-2gq1iry63p
2gq1iry63p ,
isoquinolinium, 2,2'-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl
2-(2-carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium, pentamethylene ester
AB00514743-07
DTXSID9043726
SCHEMBL7773510
AB00514743_09
AB00514743_08
STL483416
gtpl9537
FT-0765521
BCP07109
2,2'-((pentane-1,5-diylbis(oxy))bis(3-oxopropane-3,1-diyl))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium)
Q27098039
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-yl]propanoate
CS-0013365
HY-B0292
1-((3,4-dimethoxyphenyl)methyl)-2-(3-((5-((3-(1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl)propanoyl)oxy)pentyl)oxy)-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
2,2'-(pentane-1,5-diylbis(oxy(3-oxopropane-3,1-diyl)))bis(1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium)

Research Excerpts

Overview

Cisatracurium besylate is an ideal non-depolarizing muscle relaxant which is widely used in clinical application. Cis-at Racurium is a promising treatment for early moderate-severe ARDS (using Berlin definition nomenclature)

ExcerptReferenceRelevance
"Cis-atracurium is a benzylisoquinolinium neuromuscular blocking agent with an intermediate duration of action devoid of significant adverse effects previously used in pigs with a wide dosage range."( Neuromuscular block monitoring after the administration of 1 mg/kg intravenous cis-atracurium in the anaesthetized pig.
Aguilar, A; Andaluz, A; García, F; Moll, X, 2019
)
1.22
"Atracurium is a known potent histamine releaser from mast cells, but rarely can it cause IgE-mediated reactions."( [Anaphylaxis by atracurium. One case report].
Arias-Cruz, A; Domínguez-Sansores, L; González-Díaz, S; López-Cabrera, NG; Palacios-Rìos, D,
)
1.2
"Cis-atracurium is a promising treatment for early moderate-severe ARDS (using Berlin definition nomenclature) and merits further investigation in a large RCT."( Pharmacological treatments for acute respiratory distress syndrome: systematic review.
Adhikari, NK; Duggal, A; Ganapathy, A; Ratnapalan, M, 2015
)
0.9
"Cisatracurium besylate is an ideal non-depolarizing muscle relaxant which is widely used in clinical application. "( Autophagic Cell Death and Apoptosis Jointly Mediate Cisatracurium Besylate-Induced Cell Injury.
Feng, D; Li, W; Liu, X; Tian, W; Wang, J; Xia, Z; Yang, Y; Zhang, L; Zhang, X; Zhuang, H, 2016
)
1.3
"Cisatracurium is a stereoisomer of atracurium and as such has the same molecular weight."( Phlebitis as a consequence of peripheral intravenous administration of cisatracurium besylate in critically ill patients.
Meeder, AM; Rozendaal, A; van der Steen, MS; van Zanten, AR, 2016
)
1.18
"Cis-atracurium is a stereoisomer of atracurium, about five times more potent than the racemate. "( [Cis-atracurium--an equivalent substitution for atracurium in pediatric anesthesia?].
Riedel, T; Rosolski, T; Sommer, M; Voss, J, 2002
)
1.39
"Cisatracurium is a useful drug in patients when a decrease of intraocular pressure is wanted and where muscle relaxation is necessary and acceptable."( Effect of different doses of cisatracurium on intraocular pressure in sedated patients.
Heinze, G; Kontaratos, M; Oehmke, MJ; Sator-Katzenschlager, SM; Wedrich, A; Weinstabl, C, 2002
)
1.22
"Cisatracurium is a new intermediate-acting benzylisoquinolinium neuromuscular blocking agent that is one of the ten stereoisomers contained in atracurium besylate. "( A comparison of the efficacy of cisatracurium and atracurium in kidney transplantation operation.
Jirasiritham, S; Tantivitayatan, K, 2004
)
1.22
"Cisatracurium is a benzylisoquinolinium NMB drug with a duration of action not altered by ageing."( Variability of duration of action of neuromuscular-blocking drugs in elderly patients.
Arain, SR; Ebert, TJ; Ficke, DJ; Kern, S, 2005
)
0.84
"Cisatracurium is an intermediate acting, non-depolarizing neuromuscular blocking agent. "( Cisatracurium, but not mivacurium, induces apoptosis in human umbilical vein endothelial cells in vitro.
Bodrogi, F; Gruber, G; Hoffmann, G; Lirk, P; Rieder, J; Sawires, M, 2005
)
1.57
"Atracurium is a nondepolarizing skeletal muscle relaxant used to facilitate endotracheal intubation and to induce skeletal muscle relaxation during surgery or mechanical ventilation. "( Anesthesiologist suicide with atracurium.
Almarza, E; Ballesteros, S; Martínez, MA, 2006
)
2.07
"Atracurium is a new competitive neuromuscular blocking agent. "( Atracurium for intubation in man. A clinical and electromyographic study.
Katz, RL; Lee, C; Schehl, DL; Stirt, JA, 1984
)
3.15
"Atracurium is a new, non-depolarizing muscle relaxant which rapidly breaks down in vivo and appears to require neither renal nor hepatic function for its elimination. "( Use of the muscle relaxant atracurium in anephric patients: preliminary communication.
Hunter, JM; Jones, RS; Utting, JE, 1982
)
2
"Atracurium is a potent nondepolarizing muscle relaxant which is potentiated by isoflurane."( Safety and efficacy of atracurium (BW33A) in surgical patients receiving balanced or isoflurane anesthesia.
Ali, NM; Gergis, SD; Lineberry, C; Mehta, M; Sokoll, MD, 1983
)
1.3
"1. Atracurium is a novel bis-quaternary competitive neuromuscular blocking agent designed to undergo rapid non-enzymic inactivation at physiological pH and temperature. "( Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH.
Chapple, DJ; Neill, EA, 1982
)
1.16
"Atracurium is a potent competitive neuromuscular blocking agent in anesthetized man with no cardiovascular effects at doses required for paralysis. "( Evaluation of atracurium in anaesthetized man.
Hughes, R; Payne, JP, 1981
)
2.07
"Cisatracurium (Nimbex) is an intermediate-acting benzylisoquinolinium neuromuscular blocker that is one of the stereoisomers of atracurium. "( A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease.
Abou-Donia, M; Chuey, C; DePerio, M; Konstadt, SN; Reich, DL; Schwartzbach, C; Stanley, TE, 1995
)
1.15
"Atracurium is a mixture of ten stereoisomers. "( The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Abalos, A; Abou-Donia, MM; Belmont, MR; Eppich, L; Lien, CA; Quessy, S; Savarese, JJ, 1995
)
1.73
"Atracurium is an appropriate choice for producing neuromuscular blockade for periods of several days in patients with fulminant hepatic failure and renal impairment."( Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation.
Bion, JF; Bowden, MI; Chow, B; Honisberger, L; Weatherley, BC, 1993
)
2.45
"Atracurium is a mixture of ten stereoisomers."( [New muscle relaxants].
Buzello, W; Diefenbach, C, 1996
)
1.02
"Cisatracurium is a new nondepolarizing muscle relaxant. "( A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion.
Buzello, W; Diefenbach, C; Mellinghoff, H; Radbruch, L, 1996
)
1.24
"Cisatracurium is a nondepolarizing muscle relaxant with a slow onset. "( Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration.
Czeslick, E; Doenicke, AW; Hoernecke, R; Moss, J, 1998
)
1.15
"Atracurium besylate is a highly selective nondepolarizing neuromuscular blocking agent routinely used during anesthetic procedures. "( Comparative evaluation of capillary electrophoresis and high-performance liquid chromatography for the separation of cis-cis, cis-trans, and trans-trans isomers of atracurium besylate.
de Moraes, Mde L; Mattua, MF; Polakiewicz, B; Tavares, MF,
)
1.77
"Cisatracurium 0.025 mg/kg is an inadequate maintenance dose following recovery from succinylcholine and it fails to provide adequate surgical relaxation."( Duration and recovery profile of cisatracurium after succinylcholine during propofol or isoflurane anesthesia.
el-Moalem, H; Gan, TJ; Ginsberg, B; Glass, PS; Soppitt, AJ; Weatherwax, K, 1999
)
1.09
"Cisatracurium is a suitable muscle relaxant when deep and continuous levels of muscle relaxation are required in patients treated for ARDS."( The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome.
Cerf, C; Dhonneur, G; Duvaldestin, P; Gillotin, C; Lagneau, F; Mantz, J, 2001
)
1.12
"Atracurium is an effective and safe neuromuscular blocking agent in this population."( Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
Bion, JF; Bowden, MI; Chow, B; Ho, E; Weatherley, BC, 2000
)
1.31
"Atracurium is a competitive neuromuscular blocking agent which goes through Hofmann elimination. "( Assessment of atracurium during anesthesia and surgery.
Cheng, CS; Jawan, B; Lee, JH, 1990
)
2.08
"Atracurium was found to be a safe muscle relaxant with an added advantage of elimination by Hoffman's reaction."( A study of the use of atracurium in minor and major surgery.
Baloch, R; Jakhrani, NK; Muneeruddin, M, 1990
)
1.32
"Atracurium is a neuromuscular blocking agent that spontaneously degrades by Hoffmann reaction. "( Prolonged infusion of atracurium in an infant.
Paquay, T; Senterre, J; Tabardel, Y, 1990
)
2.04
"Atracurium dibesylate is a new non depolarizing muscle relaxant, metabolized by a non enzymic pathway, the Hofmann elimination. "( [Experimental pharmacology of atracurium dibesylate].
Lienhart, A; Meistelman, C, 1985
)
2
"Atracurium is a new neuromuscular blocking agent which has an unique mode of elimination by spontaneous degradation in slightly alkali solution, according to the Hofmann elimination. "( [Metabolism and pharmacokinetics of atracurium].
Colin, JN; Singlas, E, 1985
)
1.99
"Atracurium appears to be a useful relaxant, but a smaller dose than that used here should be chosen for short procedures."( Clinical comparison of atracurium and alcuronium in gynaecological surgery.
Gibbs, JM; Smeele, PQ; Woolner, DF, 1985
)
1.3
"Atracurium is a relatively new neuromuscular blocking anesthetic with known histamine release effects which has become popular in ophthalmic anesthesia. "( Eyelid anaphylactic reaction to atracurium with general anesthesia.
Nelson, CC; Sullivan, JH, 1986
)
2
"Atracurium is a mixture of ten isomers. "( The pharmacokinetics of atracurium isomers in vitro and in humans.
Graham, GG; Torda, TA; Tsui, D, 1987
)
2.02
"Atracurium is a new intermediate-acting muscle relaxant, relatively devoid of cardiovascular effect in the clinical dose range. "( Anaphylactoid reaction to atracurium.
Gellman, MD; Tetzlaff, JE, 1986
)
2.01
"Atracurium would appear to be a safe drug to provide neuromuscular relaxation in patients with plasma cholinesterase deficiency, where surgical procedures of intermediate duration are being undertaken."( Use of atracurium in a patient with plasma cholinesterase deficiency.
Donen, N, 1987
)
1.45
"Atracurium is a new non-depolarising neuromuscular blocking agent, metabolized through Hofmann elimination. "( Atracurium and severe hepatic disease: a case report.
Gyasi, HK; Naguib, M, 1985
)
3.15
"Atracurium appears to be a suitable alternative for short procedures where succinylcholine is unsuitable or contraindicated."( Atracurium for short surgical procedures: a comparison with succinylcholine.
Adu-Gyamfi, Y; Gyasi, HK; Naguib, M, 1985
)
2.43

Effects

Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes) It has an unusual intrinsic Hofmann elimination which is increased by an alkaline environment and increased temperature.

Cisatracurium besylate has been determined by fast and highly sensitive spectrofluorimetric method based on measuring the fluorescence intensity of its methanolic solution at 312 nm after excitation at 230 nm (Method I) Atracuriam has been studied in 16 patients divided into two groups, the first of which suffering from chronic renal failure.

ExcerptReferenceRelevance
"Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes)."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.82
"Atracurium has an unusual intrinsic Hofmann elimination which is increased by an alkaline environment and increased temperature. "( The stability of atracurium in clinical practice.
Meyer-Witting, M; Russell, WJ, 1990
)
2.06
"Cisatracurium besylate has been determined by fast and highly sensitive spectrofluorimetric method based on measuring the fluorescence intensity of its methanolic solution at 312 nm after excitation at 230 nm (Method I). "( Conventional and first derivative synchronous spectrofluorimetric methods for the simultaneous determination of cisatracurium and nalbuphine in biological fluids.
Belal, F; El Sharkasy, ME; Salim, MM; Walash, M, 2020
)
1.39
"Atracurium has been reported to have minimal haemodynamic effects in healthy patients. "( Haemodynamic effects of bolus injections of atracurium in patients with coronary artery disease.
Alban, JC; Lineberry, CC; Lowenstein, E; Machaj, VR; Philbin, DM; Schneider, RC; Tomichek, RC, 1983
)
1.97
"Atracurium has been evaluated in anaesthetized patients using the single twitch and tetanic responses of the adductor pollicis muscles. "( Clinical assessment of atracurium using the single twitch and tetanic responses of the adductor pollicis muscles.
Hughes, R; Payne, JP, 1983
)
2.02
"Atracurium has four chiral centers and the marketed product is a mixture of ten optical and geometric isomers. "( Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.
Hill, DA; Maehr, RB; Savarese, JJ; Turner, GL; Wastila, WB, 1996
)
2.02
"Cisatracurium has neuromuscular blocking effects identical to those of atracurium, is more potent, and does not produce cardiovascular effects or increase plasma histamine concentrations."( Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.
Hill, DA; Maehr, RB; Savarese, JJ; Turner, GL; Wastila, WB, 1996
)
1.2
"Cisatracurium has been considered a drug with a relatively slow onset but that has the significant benefit of being devoid of chemically mediated histamine release. "( Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration.
Czeslick, E; Doenicke, AW; Hoernecke, R; Moss, J, 1998
)
1.15
"Cisatracurium has proven useful in intensive care because of its hemodynamic stability, which is comparable to that of steroid derivatives but with faster recovery from blockade once administration is discontinued."( [Cisatracurium].
Carrascosa, F; Ortiz, JR; Percaz, JA,
)
1.2
"Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes)."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.82
"Atracurium has an unusual intrinsic Hofmann elimination which is increased by an alkaline environment and increased temperature. "( The stability of atracurium in clinical practice.
Meyer-Witting, M; Russell, WJ, 1990
)
2.06
"Atracurium has advantages in this respect when neuromuscular monitoring is not used during operation."( Residual curarisation: a comparative study of atracurium and pancuronium.
Andersen, BN; Juhl, B; Madsen, JV; Schurizek, BA, 1988
)
1.25
"Atracurium has been studied in 16 patients divided into two groups, the first of which suffering from chronic renal failure. "( [The use of atracurium in subjects with chronic renal insufficiency].
Amato, F; Tramontano, R,
)
1.95

Actions

Cisatracurium can inhibit the proliferation, migration and invasion of breast cancer MDA-MB-231 cells. Its mechanism is related to the down-regulation of miR-3174 expression in cells.

ExcerptReferenceRelevance
"Cisatracurium can inhibit the proliferation, migration and invasion of breast cancer MDA-MB-231 cells, and its mechanism is related to the down-regulation of miR-3174 expression in cells."( Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174.
Ma, W; Yang, X, 2020
)
1.69
"Atracurium had a lower potency in anephric patients."( Atracurium and pancuronium in renal insufficiency.
Berntman, L; Rosberg, B; Shweikh, I; Yousef, H, 1989
)
2.44
"Atracurium did not cause cardiovascular changes."( Neuromuscular and cardiovascular effects of atracurium administered to healthy horses anesthetized with halothane.
Arpin, D; Hildebrand, SV, 1988
)
1.26
"Atracurium was used to produce neuromuscular blockade in a patient with dystrophia myotonica. "( Dystrophia myotonica and atracurium. A case report.
Healy, TE; McGuinness, K; Nightingale, P, 1985
)
2.02

Treatment

Cisatracurium treatment suppressed the viability and metastasis of HCT116 and SW480 cells in a concentration-dependent manner. activating TGF-β/SMAD2/3 signalling significantly reversed these effects. Cisat Racurium besilate treatment restrained the proliferation and promoted the apoptosis of AGS cells.

ExcerptReferenceRelevance
"Cisatracurium besilate treatment restrained the proliferation and promoted the apoptosis of AGS cells."( Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling.
Liu, Y; Wu, Y; Yuan, J; Zhou, Q, 2021
)
1.76
"Cisatracurium treatment suppressed the viability and metastasis of HCT116 and SW480 cells in a concentration-dependent manner, whereas activating TGF-β/SMAD2/3 signalling significantly reversed these effects. "( Cisatracurium regulates the CXCR4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling.
Chen, JM; Shan, GF; Wang, L; Xia, YZ; Yang, H; Zha, J; Zhang, XS, 2021
)
1.86

Toxicity

The incidence of noncardiovascular adverse events (increase in peak airway pressure > 5 cmH2O, tidal volume decrease > 10%, rashes, and wheezing) did not differ between atracurium (17%) and vecuronium (7%). The authors conclude that, in patients with asthma, adverse cardiovascular events are more common with at Racurium than with vecur onium.

ExcerptReferenceRelevance
" Acrylates appear to be the toxic agent."( Potentiation of atracurium toxicity in isolated rat hepatocytes by inhibition of its hydrolytic degradation pathway.
Klaunig, JE; Nigrovic, V; Schultz, NE; Smith, SL, 1987
)
0.62
" The customary assumption was made that the exudation of LDH reflects the toxic effects of the relaxants."( Comparative toxicity of atracurium and metocurine in isolated rat hepatocytes.
Klaunig, JE; Nigrovic, V; Schultz, NE; Smith, SL; Wajskol, A, 1986
)
0.58
" No specific adverse effects were found despite administration of supraparalysing doses."( Toxicity testing of atracurium.
Dayan, AD; Follenfant, M; James, DA; Lovell, R; Lucke, JN; Medd, R; Moore, WB; Morgan, M; Skarpa, M; Thomson, PM, 1983
)
0.59
"To determine which of atracurium or vecuronium is associated with fewer adverse cardiovascular and pulmonary events in high-risk patients, the authors administered these drugs to patients with known asthma."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
2.05
"1 mg/kg vecuronium over 5-10 s, and a blinded observer recorded cardiovascular, pulmonary, and cutaneous signs of adverse reactions for 6 min."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
1.73
" The incidence of noncardiovascular adverse events (increase in peak airway pressure > 5 cmH2O, tidal volume decrease > 10%, rashes, and wheezing) did not differ between atracurium (17%) and vecuronium (7%)."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
1.93
"The authors conclude that, in patients with asthma, adverse cardiovascular events are more common with atracurium than with vecuronium."( Atracurium versus vecuronium in asthmatic patients. A blinded, randomized comparison of adverse events.
Caldwell, JE; Fisher, DM; Lau, M, 1995
)
1.95
" Intubation conditions 60 sec after administration of muscle relaxant and immediate cardiovascular disturbances or adverse events during the hospital stay were noted by blinded observers."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.53
" The incidence of adverse events and the cardiovascular profiles for the two drugs were similar, although one patient receiving atracurium experienced transient flushing of the head and neck."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.74
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The use of the basophil activation marker CD63 as a screening tool in selecting a safe muscle relaxant is presented."( Anaphylaxis to vecuronium: the use of basophil CD63 expression as a possible screening tool to identify a safe alternative.
Appadurai, IR; Sudheer, PS, 2007
)
0.34
"The main objective of this study is to evaluate the economic and adverse drug reactions prevalence and differences between cisatracurium and atracurium the two non-depolarizing NMB drugs, which are widely used in adult patients undergoing surgery with general anesthesia in a teaching Hospital in Iran."( Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia.
Amini, S; Hayatshahi, A; Javadi, M; Movafegh, A; Sharifnia, H; Torkamandi, H, 2013
)
0.86
"A cost analysis and adverse drug reactions (ADR) monitoring were performed."( Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia.
Amini, S; Hayatshahi, A; Javadi, M; Movafegh, A; Sharifnia, H; Torkamandi, H, 2013
)
0.65

Pharmacokinetics

Atracurium's recovery phase half-life was 14. Currently recommended loading dose might not lead to the desired pharmacodynamic response in critically ill patients.

ExcerptReferenceRelevance
" The pharmacokinetic profile was affected by age, sex and anaesthetic technique."( Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium.
Hunter, JM; Parker, CJ; Snowdon, SL, 1992
)
0.52
"A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine."( Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.
Banoub, M; Nigrovic, V, 1992
)
0.74
" It offers a solution to the problem of adapting pharmacokinetic and pharmacodynamic data to individuals when using mean data as starting values for drug therapy."( Use of a pharmacokinetic-dynamic model for the automatic feedback control of atracurium.
Olkkola, KT; Schwilden, H, 1991
)
0.51
" These estimates of the pharmacokinetic parameters of atracurium are markedly different from those derived from pharmacokinetic analysis of single bolus dose data."( Pharmacokinetics of atracurium during continuous infusion.
Beemer, GH; Bjorksten, AR; Crankshaw, DP, 1990
)
0.85
"0 min) infusion of atracurium was administered until twitch tension was suppressed by approximately 70%, and atracurium plasma concentration and twitch tension data were used to determine pharmacokinetic and pharmacodynamic parameters for each patient."( Pharmacokinetics and pharmacodynamics of atracurium in the elderly.
Caldwell, JE; Canfell, PC; Fahey, MR; Fisher, DM; Heier, T; Kitts, JB; Miller, RD; Spellman, MJ, 1990
)
0.87
" A two-compartment pharmacokinetic model, adapted to account for elimination of atracurium from both central and peripheral compartments, was fit to the plasma concentration data; an effect-compartment model was fit to the twitch tension data."( Pharmacokinetics and pharmacodynamics of atracurium in infants and children.
Canfell, PC; Fisher, DM; Miller, RD; Spellman, MJ, 1990
)
0.77
" Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively)."( Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.
Agoston, S; Vandenbrom, RH; Wierda, JM, 1990
)
0.73
" The elimination half-life (T1/2 beta) of atracurium was significantly longer in the elderly group (23."( Pharmacokinetics of atracurium and laudanosine in the elderly.
Hunter, JM; Kent, AP; Parker, CJ, 1989
)
0.86
" There were no significant differences in the mean value of any pharmacokinetic parameter (clearance, V1, V beta, alpha and beta half-lives)."( Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans.
Dwersteg, JF; Haschke, RH; Heimbach, DM; Marathe, PH; Pavlin, EG; Slattery, JT, 1989
)
0.51
"The authors used pharmacokinetic and pharmacodynamic modeling to explain the time course of neuromuscular blockade following single or multiple doses of three nondepolarizing muscle relaxants."( A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants.
Fisher, DM; Rosen, JI, 1986
)
0.27
" Spontaneous degradation of atracurium in plasma is the major route of elimination in man and contributes to a short elimination half-life (approximatively 20 min)."( [Metabolism and pharmacokinetics of atracurium].
Colin, JN; Singlas, E, 1985
)
0.84
" It appears that pharmacodynamic mechanisms are involved, and inactivity and disuse atrophy are not necessary in rats for development of resistance to nondepolarizing muscle relaxants after thermal injury."( Resistance to atracurium in thermally injured rats. The roles of time, activity, and pharmacodynamics.
Butler, SH; Haschke, RH; Howard, ML; Marathe, P; Pavlin, EG; Slattery, JT, 1988
)
0.64
" The cis-cis group broke down in a monoexponential manner with a half-life of 23."( The pharmacokinetics of atracurium isomers in vitro and in humans.
Graham, GG; Torda, TA; Tsui, D, 1987
)
0.58
"The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease."( Pharmacokinetics of atracurium and its metabolites.
Ward, S; Weatherley, BC, 1986
)
0.88
" With regard to pharmacokinetic or pharmacodynamic parameters, we found no statistically significant differences between normal and anephric patients."( Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.
Ali, HH; Batson, AG; Cosimi, AB; deBros, FM; deBros, J; Goudsouzian, N; Lai, A; Savarese, JJ; Scott, R, 1986
)
0.54
" The plasma concentrations of atracurium for each patient were fitted to a two-compartment pharmacokinetic model."( The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
Canfell, C; Castagnoli, K; Fahey, MR; Fisher, DM; Hennis, PJ; Miller, RD; Rupp, SM; Sharma, M, 1984
)
0.82
" An individual two-compartment pharmacokinetic model was used for interpretation."( Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose).
Corall, IM; Neill, EA; Ward, S; Weatherley, BC, 1983
)
0.59
" A two-compartment model was fitted to the 51W89 plasma concentration data using the NONMEM program, to estimate pharmacokinetic variables and to determine the influence of renal failure, age, weight and sex."( Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1995
)
0.57
"To examine the ability to determine clinically important pharmacokinetic and pharmacodynamic parameters of atracurium by the analysis of the time course of effect without the use of plasma concentration data."( Pharmacokinetic analysis of the time course of effect of atracurium.
Graham, GG; Torda, TA; Warwick, NR, 1995
)
0.75
" The half-life of elimination estimated from the fourth twitch was similar to that from the first twitch."( Pharmacokinetic analysis of the time course of effect of atracurium.
Graham, GG; Torda, TA; Warwick, NR, 1995
)
0.54
"The analysis of high-resolution effect data is capable of giving pharmacokinetic and pharmacodynamic parameters with clinically acceptable accuracy within a short sampling time, without resorting to laboratory analysis."( Pharmacokinetic analysis of the time course of effect of atracurium.
Graham, GG; Torda, TA; Warwick, NR, 1995
)
0.54
" Pharmacokinetic analysis was performed using NONMEM."( Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium.
Bjorksten, AR; Leslie, K; Moayeri, A; Sessler, DI, 1995
)
0.51
" Pharmacokinetic simulations suggest that vecuronium's cumulation occurs as recovery shifts from distribution to elimination whereas atracurium's recovery always occurs during elimination."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
0.78
" Plasma was sampled for 128 min to determine muscle relaxant concentrations; pharmacodynamic modeling was used to determine effect-compartment drug concentrations (Ce)."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
0.58
" Atracurium's recovery phase half-life was 14."( Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
Fisher, DM; Gruenke, L; Hart, P; Lau, M; Sharma, ML; Wright, PM, 1994
)
1.49
" A four-parameter threshold pharmacodynamic model was fitted to the data in each patient."( Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium.
Hunter, JM; Parker, CJ; Snowdon, SL, 1993
)
0.52
" Atracurium can be used as a pharmacokinetic benchmark; it has at least two distinct metabolic pathways, of which Hofmann elimination and ester hydrolysis are the most significant."( Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants.
Hull, CJ, 1995
)
1.2
" The elimination half-life of 51W89 was significantly longer in renal failure patients than in healthy controls (38."( Pharmacokinetics of 51W89: preliminary data.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1995
)
0.29
" There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0."( Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients.
Boyd, AH; Eastwood, NB; Hull, CJ; Sorooshian, SS; Stafford, MA; Wright, PM, 1996
)
0.56
" Pharmacokinetic parameters were determined assuming that elimination occurred from the central compartment only."( Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.
Diaz, J; Lien, CA; Matteo, RS; Ornstein, E; Ostapkovich, ND; Wolf, KB, 1996
)
0.56
" Elimination half-life was minimally prolonged in the elderly (25."( Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.
Diaz, J; Lien, CA; Matteo, RS; Ornstein, E; Ostapkovich, ND; Wolf, KB, 1996
)
0.56
" Pharmacokinetic variables were determined using non-compartmental methods."( Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation.
Cook, DR; De Wolf, AM; Freeman, JA; Kerls, S; Kisor, DF; Scott, VL; Smith, DA; Tullock, W, 1996
)
0.56
" Using the NONMEM program, a single compartment pharmacokinetic model was fitted to the plasma concentrations of cis-atracurium and the cis-cis, cis-trans and trans-trans isomers of atracurium."( Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit.
Boyd, AH; Eastwood, NB; Hunter, JM; Parker, CJ, 1996
)
0.73
" Pharmacokinetic values were evaluated by use of multivariant stepwise linear regression analysis."( Pharmacokinetics, effects on renal function, and potentiation of atracurium-induced neuromuscular blockade after administration of a high dose of gentamicin in isoflurane-anesthetized dogs.
Cooper, J; Hartsfield, SM; Martinez, EA; Mealey, KL; Mercer, DE; Slater, MR; Wooldridge, AA, 1996
)
0.53
" The analyses included limited Cp-time data randomly collected from 186 patients in efficacy/safety studies and full Cp-time data from 55 patients in pharmacokinetic studies."( Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium.
Fiedler-Kelly, J; Grasela, TH; Phillips, L; Schmith, VD, 1997
)
0.52
"min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34."( A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients.
Hunter, JM; Parker, CJ; Smith, CE; van Miert, MM, 1997
)
0.8
" Other pharmacodynamic parameters did not differ significantly."( [Cisatracurium in patients with compromised kidney function. Pharmacodynamic and intubation conditions under isoflurane-nitrous oxide anesthesia].
Bunk, S; Clausen, T; Czeslick, E; Menzel, M; Radke, J; Soukup, J, 1998
)
0.86
" A nontraditional two-compartment pharmacokinetic model with elimination from central and peripheral compartments was used."( Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia.
Fiset, P; Tran, TV; Varin, F, 1998
)
0.56
"To determine the hemodynamic and pharmacodynamic effects of rapid bolus administration of cisatracurium compared with vecuronium."( A two-center study evaluating the hemodynamic and pharmacodynamic effects of cisatracurium and vecuronium in patients undergoing coronary artery bypass surgery.
Cannon, JE; Carrier, M; Dupont, C; Gagnon, L; Rosenbloom, M; Roy, M; Searle, NR; Thomson, I, 1999
)
0.75
" This method has been used to determine the pharmacokinetic profile of atracurium and laudanosine in patients with acute respiratory distress syndrome."( High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics.
Audran, M; Bressolle, F; Farenc, C; Lefrant, JY; Mazerm, I, 1999
)
0.77
" Pipecuronium resembles pancuronium in its pharmacokinetic and neuromuscular blocking profile, but is devoid of cardiovascular effects."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.3
"For anesthetic drugs undergoing nonorgan-based elimination, there is a definite trend towards using pharmacokinetic (PK) models in which elimination can occur from both central (k10) and peripheral compartments (k20)."( Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.
Donati, F; Laurin, J; Nekka, F; Varin, F, 1999
)
0.3
" A preliminary independent analysis was done to estimate the individual pharmacokinetic parameters; data were consistent with a one-compartment model."( Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients.
Audran, M; Bressolle, F; Farenc, C; Lefrant, JY, 2001
)
0.57
" The pharmacokinetic variables observed in these severely ill patients were similar to those of anesthetized patients."( The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome.
Cerf, C; Dhonneur, G; Duvaldestin, P; Gillotin, C; Lagneau, F; Mantz, J, 2001
)
0.61
" The mean terminal half-life (t1/2) for atracurium was 18."( Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
Bion, JF; Bowden, MI; Chow, B; Ho, E; Weatherley, BC, 2000
)
0.86
" The authors used published data to evaluate the effect of modeling assumptions on pharmacodynamic estimates."( Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
Fisher, DM; Paul, M, 2002
)
0.31
"The erroneous assumption that Cp decreases monotonically after bolus administration affects accuracy of pharmacodynamic estimates with doses producing rapid, complete twitch depression."( Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
Fisher, DM; Paul, M, 2002
)
0.31
" Pharmacodynamic results were comparable to those obtained in pediatric studies during halothane or opioid anesthesia with the exception of a longer recovery to 25% baseline."( Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia.
Imbeault, K; Varin, F; Withington, DE, 2006
)
0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic analyses were performed using two compartmental models assuming central or both central and peripheral elimination."( Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations.
Chen, C; Varin, F; Yamaguchi, N, 2009
)
0.62
" Patients received cisatracurium single 100 µg kg-1 bolus dose, serial arterial blood samples were collected and assayed for pharmacokinetic analysis."( Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate.
Dahaba, AA; Dong, H; Oettl, K; Reibnegger, G; Suljevic, I; Xiao, Z; Xiong, L, 2013
)
0.93
" Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37."( Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate.
Dahaba, AA; Dong, H; Oettl, K; Reibnegger, G; Suljevic, I; Xiao, Z; Xiong, L, 2013
)
0.62
"ANH altered some pharmacokinetic parameters such as significantly larger volumes of distribution."( Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate.
Dahaba, AA; Dong, H; Oettl, K; Reibnegger, G; Suljevic, I; Xiao, Z; Xiong, L, 2013
)
0.62
" Furthermore, significantly delayed pharmacodynamic responses to cisatracurium were observed in patients with septal defects."( Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects.
Lu, C; Peng, X; Wang, S; Wu, B; Wu, Z; Ye, X, 2016
)
1.06
" Pharmacokinetic and pharmacodynamic studies of cisatracurium in critically ill patients are still limited."( Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
Dilokpattanamongkol, P; Nosoongnoen, W; Panusitthikorn, P; Suthisisang, C; Tangsujaritvijit, V, 2022
)
1.21
" The achievement of the desired pharmacodynamic response was evaluated by both 1) clinical assessment and 2) train-of-four monitoring."( Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
Dilokpattanamongkol, P; Nosoongnoen, W; Panusitthikorn, P; Suthisisang, C; Tangsujaritvijit, V, 2022
)
0.96
"The one-compartment model best described the plasma pharmacokinetic parameters of cisatracurium."( Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
Dilokpattanamongkol, P; Nosoongnoen, W; Panusitthikorn, P; Suthisisang, C; Tangsujaritvijit, V, 2022
)
1.18
"The currently recommended loading dose of cisatracurium might not lead to the desired pharmacodynamic response in critically ill patients with respiratory failure."( Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
Dilokpattanamongkol, P; Nosoongnoen, W; Panusitthikorn, P; Suthisisang, C; Tangsujaritvijit, V, 2022
)
1.21

Compound-Compound Interactions

ExcerptReferenceRelevance
"Intravenous lidocaine plays a significant role in the hemodynamic stability of patients under general anesthesia without exerting any additional impact on the NMB, even combined with magnesium sulfate."( Lidocaine combined with magnesium sulfate preserved hemodynamic stability during general anesthesia without prolonging neuromuscular blockade: a randomized, double-blind, controlled trial.
de Boer, HD; Garcia, LV; Oliveira-Paula, GH; Paula-Garcia, WN, 2021
)
0.62

Dosage Studied

Atracurium is used in thiopental-fentanyl-N2O-O2-anaesthesia. The aim of this study was to evaluate the influence of acute isovolaemic haemodilution on the dose-response and time-course of action.

ExcerptRelevanceReference
" The neuromuscular effects of desflurane or isoflurane alone, and the dose-response relationship, time course, and reversibility of the neuromuscular effects of atracurium with either anesthetic, were examined in detail and compared using electromyographic quantification of the response of the first dorsal interosseous muscle to train-of-four (TOF) stimulation of the ulnar nerve."( Desflurane potentiates atracurium in humans: a comparative study with isoflurane.
Chen, BJ; Cheng, ML; Kwan, WF; Lee, C; Tsai, SK,
)
0.64
" Neither cardiovascular side effects nor signs of histamine release occurred after the injection of both muscle relaxants at our dosage level."( [Comparative studies of atracurium and vecuronium for medium-length surgical procedures in infants and young children].
Grundmann, U; Ismaily, AJ; Kleinschmidt, S; Motsch, J, 1991
)
0.59
" The described controller provides reasonable control of atracurium dosing at different degrees of neuromuscular blockade."( Model-based adaptive closed-loop feedback control of atracurium-induced neuromuscular blockade.
Apffelstaedt, C; Olkkola, KT; Schwilden, H, 1991
)
0.78
" Cumulative dose-response curves for atracurium were obtained by the injection of doses followed by an infusion to compensate for elimination."( Potency of atracurium on masseter and adductor pollicis muscles in children.
Bevan, DR; Bevan, JC; Donati, F; Plumley, MH; Saddler, JM, 1990
)
0.94
"To determine the influence of enflurane on the ability of edrophonium to antagonize atracurium block, dose-response curves were constructed for edrophonium in the presence of 0%, 1% and 2% enflurane, and for 2% enflurane discontinued at the time of administration of edrophonium."( Edrophonium antagonism of atracurium during enflurane anaesthesia.
Bevan, DR; Donati, F; Gill, SS, 1990
)
0.8
" the pretreatment with Alcuronium can enhance intentionally the duration of action of Atracurium and spare total dosage of muscle relaxants at the same time."( [Atracurium--increased duration of its effect following alcuronium].
Janda, A; Mühlsteiger, B; Schwarz, S, 1990
)
1.41
" The relative cutaneous histamine-releasing ability of each drug was derived from calculated dose-response relationships."( Comparative cutaneous histamine release by neuromuscular blocking agents.
Galletly, DC, 1986
)
0.27
" The dosage range for atracurium given by infusion (0."( Atracurium infusion in total intravenous anesthesia.
Nilsson, A; Persson, MP; Tamsen, A, 1987
)
2.03
" Up to now it is unknown if a clinical dosage of atracurium exists where no clinically relevant histamine release occurs."( [Cardiovascular reactions and histamine release following atracurium--a problem of dosage?].
Triene, M; Tryba, M; Wruck, G; Zenz, M, 1988
)
0.77
"To determine the potencies of edrophonium and neostigmine as antagonists of nondepolarizing neuromuscular blockade produced by atracurium and vecuronium, dose-response curves were constructed for both antagonists when given at 10% spontaneous recovery of first twitch height."( Dose-response relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade.
Bevan, DR; Donati, F; Smith, CE, 1989
)
0.71
" We conclude that there is no clinical indication that the dosage of atracurium and vecuronium during inhalation anesthesia should be reduced, but the doses of pipecuronium and pancuronium should be reduced when prolonged paralysis is not desired."( Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.
Agoston, S; Hermans, J; Ket, JM; Koot, HW; Rashkovsky, OM; Swen, J, 1989
)
0.51
" The most important elements of this investigation involve: the priming technique, dosage variations of atracurium in respect to the two different administration techniques (further doses, continuous infusion), anticholinesterases need during neuromuscular block reverse and average neuromuscular recovery time without anticholinesterases."( [Atracurium in general surgery].
Bottari, W; Camorali, C; Favilli, L; Nieddu, M; Salvi, E; Tamponi, G, 1989
)
1.4
" The two dose-response points thus acquired resulted in the individual two-dose dose-response curve."( Two-dose technique to create an individual dose-response curve for atracurium.
Meretoja, OA; Wirtavuori, K, 1989
)
0.51
" Cumulative dose-response curves were obtained during thiopentone-nitrous oxide-fentanyl anaesthesia."( Cumulative dose-response curves for atracurium in patients with myasthenia gravis.
Bevan, DR; Donati, F; Smith, CE, 1989
)
0.55
" The sizes of the bolus injections were based on previously determined cumulative dose-response relationships."( Neuromuscular blocking effects of atracurium, vecuronium and pancuronium during bolus and infusion administration.
Gramstad, L; Lilleaasen, P, 1985
)
0.55
"25 mg/kg) during anesthesia with O2/N2O/fentanyl, to generate dose-response curves for the relaxants."( The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium.
Diaz, J; Matteo, RS; Ornstein, E; Schwartz, AE; Silverberg, PA; Young, WL, 1987
)
0.5
" In order to simulate clinical practice--which entails long-term oral treatment and significant reductions in systolic blood pressure--CA were administered to rats orally (by gavage) for 8 days at a dosage that induced a systolic blood pressure decrease of not more than 25 +/- 5 mmHg."( [Atracurium and vecuronium: interaction with three orally administered calcium antagonists in animal experiments].
Dozier, SE; Fulfer, RT; Ilias, WK; Williams, CH, 1987
)
1.18
" Although the time to maximum NMB following divided doses of pancuronium, atracurium or vecuronium is significantly longer than that for succinylcholine, divided dosing significantly decreases the time required to reach maximal NMB."( Accelerated onset of non-depolarizing neuromuscular blocking drugs: pancuronium, atracurium and vecuronium. A comparison with succinylcholine.
Gergis, SD; Mehta, MP; Sokoll, MD, 1988
)
0.73
"The ability of cumulative dose-response techniques to obtain accurate data is most likely limited by redistribution and elimination of the drug during the study period."( Cumulative dose-response with infusion: a technique to determine neuromuscular blocking potency of atracurium and vecuronium.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.49
" These simulations allow the user to contrast the time-course of relaxation to be expected with various dosage regimens."( Simulating the time-course of clinical paralysis.
Shanks, CA, 1988
)
0.27
"To measure the ability of neostigmine and edrophonium to reverse moderate and profound atracurium blockade, dose-response relationships were established for these reversal agents given at 1% and 10% twitch height recovery."( Dose-response relationships for edrophonium and neostigmine as antagonists of moderate and profound atracurium blockade.
Bevan, DR; Donati, F; Smith, CE, 1989
)
0.72
"We were interested in determining the dose-response relationship of atracurium in children (2-10 yr) during nitrous oxide-isoflurane anesthesia (1%) and the atracurium infusion rate required to maintain about 95% neuromuscular blockade during nitrous oxide-halothane (0."( Atracurium infusion requirements in children during halothane, isoflurane, and narcotic anesthesia.
Brandom, BW; Cook, DR; Fehr, B; Lineberry, CG; Rudd, GD; Woelfel, SK, 1985
)
1.95
"To assess the influence of age on the dose-response relationship of atracurium in paediatric patients during thiopental-fentanyl-N2O-O2-anaesthesia, we studied 85 patients from neonates to adolescents."( Influence of age on the dose-response relationship of atracurium in paediatric patients.
Meretoja, OA; Wirtavuori, K, 1988
)
0.76
" In the dosage levels described here, atracurium hardly exercised any action on pulse rate and blood pressure."( [Repeated injection of atracurium for muscle relaxation in abdominal surgery].
Klein, G; Leuwer, M, 1988
)
0.86
"The potency of atracurium was determined in neonates, infants and children during thiopentone-fentanyl-nitrous oxide in oxygen anaesthesia using single dose-response curves."( Comparison of atracurium-induced neuromuscular blockade in neonates, infants and children.
Baker, RD; Meakin, G; Morris, P; Shaw, EA, 1988
)
0.99
" Dose-response curves were established using least-squares regression techniques."( Evaluation of atracurium neuromuscular blockade in paediatric patients with burn injury.
Martyn, JA; Mills, AK, 1988
)
0.64
" In reduced dosage and with careful neuromuscular monitoring, atracurium appears to be a reasonable and safe choice of myasthenic patients to provide surgical relaxation."( [Curarization of the myasthenia patient by atracurium].
Cozian, A; Juge, C; Lepage, JY; Malinge, M; Souron, R, 1987
)
0.78
" It was concluded that glycopyrrolate enhanced atracurium-induced neuromuscular blockade in the rat diaphragm preparation, and that this effect should be noted when dosing glycopyrrolate in man."( Glycopyrrolate intensifies neuromuscular blockade produced by atracurium in the rat diaphragm preparation.
Altinel, A; Dark, CH; Jones, CJ; Wali, FA, 1987
)
0.77
" A dose-response curve based upon a simple model of drug receptor interaction at the neuromuscular junction was fitted to the experimental points by least squares and is able to provide a useful explanation of clinically observed behaviour."( Computer-controlled muscle paralysis with atracurium in the sheep.
Brown, WA; Cass, NM; Lampard, DG; Ng, KC, 1986
)
0.54
"Intubating conditions following 2 different dosage levels of atracurium, a new non-depolarising muscle relaxant was compared with suxamethonium."( Conditions for endotracheal intubation after atracurium and suxamethonium.
Famewo, CE, 1986
)
0.77
" In reduced dosage and with careful neuromuscular monitoring, atracurium is safe to use in the myasthenic patient."( Atracurium in the myasthenic patient.
Bell, CF; Florence, AM; Hunter, JM; Jones, RS; Utting, JE, 1984
)
1.95
"Neuromuscular blocking agents can be evaluated in anesthetized cats, dogs, or rhesus monkeys using dose-response relationships to assess the degree of separation between neuromuscular blocking activity and effects on cardiovascular and autonomic systems."( Experimental and clinical evaluation of neuromuscular blocking agents.
Hughes, R, 1984
)
0.27
"The potencies of atracurium, Org NC 45 and pancuronium were determined using cumulative dose-response curves."( Dose-response relation for atracurium, ORG NC 45 and pancuronium.
Gramstad, L; Lilleaasen, P, 1982
)
0.9
" and an infusion (150 micrograms kg-1 min-1 for 30 min and 75 micrograms kg-1 min-1 thereafter) on the pharmacodynamics and dose-response curves of atracurium and vecuronium were studied in 52 healthy (ASA I or II) patients."( Some effects of diisopropyl phenol (ICI 35 868) on the pharmacodynamics of atracurium and vecuronium in anaesthetized man.
Booij, LH; Crul, JF; Fragen, RJ; Robertson, EN; van Egmond, J, 1983
)
0.7
" Atracurium also does not depend on hepatic function for metabolism; however, vecuronium may require dosing adjustments in hepatic disease."( Atracurium and vecuronium: two unique neuromuscular blocking agents.
Conner, CS, 1984
)
2.62
" No cardiovascular effects were observed in this dosage range."( Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant.
Ali, HH; Basta, SJ; Cato, AE; Cloutier, G; Gionfriddo, M; Lineberry, C; Savarese, JJ; Sunder, N, 1982
)
0.57
" To estimate dose-response relationships, three groups of five infants received 60, 80, and 100 micrograms/kg atracurium, respectively; another ten infants received 300 micrograms/kg (2 X ED95)."( Clinical pharmacology of atracurium in infants.
Brandom, BW; Cook, DR; Fehr, BL; Rudd, GD; Woelfel, SK, 1984
)
0.78
"4 mg/kg and dose-response curves were established for both balanced and isoflurane anesthetic techniques."( Safety and efficacy of atracurium (BW33A) in surgical patients receiving balanced or isoflurane anesthesia.
Ali, NM; Gergis, SD; Lineberry, C; Mehta, M; Sokoll, MD, 1983
)
0.58
"The potency of atracurium was determined in adolescents and children during nitrous oxide-halothane and nitrous oxide-thiopentone-fentanyl anaesthesia using single dose-response curves."( Clinical pharmacology of atracurium in paediatric patients.
Brandom, BW; Cook, DR; Rudd, GD, 1983
)
0.92
" Comparison of the results with those from 15 patients given suxamethonium 50 mg showed that atracurium in this dosage took longer to produce complete ablation of the twitch responses but that it lasted longer (about 40 min)."( Use of atracurium during general surgery monitored by the train-of-four stimuli.
Hunter, JM; Jones, RS; Utting, JE, 1982
)
0.94
" Subsequently he had an adequate response with a standard dosage of pancuronium."( Atracurium resistance in a critically Ill patient.
Hoey, LL; Nahum, A; Tschida, SJ; Vance-Bryan, K,
)
1.57
" Dosage titration was initially based on clinical assessment; however, on day 4 of atracurium, TOF monitoring was initiated."( Inconsistency with train-of-four monitoring in a critically ill paralyzed patient.
Hoey, LL; Tschida, SJ; Vance-Bryan, K,
)
0.36
" We compared the dose-response and recovery pharmacodynamics of a new intermediate-acting NMB drug, cisatracurium besylate, to the intermediate-acting NMB drug, vecuronium (VEC), in a prospective, randomized, double-blind, multicenter study in critically ill adults."( Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients.
Bowton, DL; Cardenas, VJ; Casale, EJ; Coursin, DB; Ford, SR; Howard, D; Murray, MJ; Prielipp, RC; Scuderi, PE; Vender, J, 1995
)
0.73
" Equations describing the theoretic time course of concentrations in the effect compartment and the dose-response relationship were fitted simultaneously to these data; the parameters of these equations derived from the fit of two doses were used to predict the response to a third dose."( Pharmacokinetic analysis of the time course of effect of atracurium.
Graham, GG; Torda, TA; Warwick, NR, 1995
)
0.54
"The inability of edrophonium to rapidly reverse a deep nondepolarizing neuromuscular block may be due to inadequate dosage or a ceiling effect to antagonism of neuromuscular block by edrophonium."( The maximum depth of an atracurium neuromuscular block antagonized by edrophonium to effect adequate recovery.
Beemer, GH; Bjorksten, AR; Goonetilleke, PH, 1995
)
0.6
" Cumulative dose-response curves were constructed using the logit transformation of the neuromuscular effect versus the logarithm of the cumulative dose of edrophonium."( The maximum depth of an atracurium neuromuscular block antagonized by edrophonium to effect adequate recovery.
Beemer, GH; Bjorksten, AR; Goonetilleke, PH, 1995
)
0.6
" The first 30 patients were randomized to receive either atracurium or vecuronium to create individual dose-response curves for these muscle relaxants."( Potency and maintenance requirement of atracurium and vecuronium given alone or together.
Erkola, O; Meretoja, OA; Rautoma, P, 1995
)
0.81
" These guidelines recommend clinical indications for these agents and dosing ranges reflecting current medical opinion."( The role of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients.
May, JR; Rutkowski, AF, 1994
)
0.29
" An individual dose-response curve of the atracurium-vecuronium combination was determined for every patient and its potency compared with that of the parent agents alone."( Synergism between atracurium and vecuronium in infants and children during nitrous oxide-oxygen-alfentanil anaesthesia.
Jalkanen, L; Meretoja, OA; Taivainen, T; Wirtavuori, K, 1994
)
0.89
" We evaluated dose-response data and neuromuscular effects of 2 x ED95 dose and maintenance doses of 51W89 during halothane anaesthesia in 68 children, 2-12 yr old."( Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia.
Meretoja, OA; Taivainen, T; Wirtavuori, K, 1995
)
0.55
" This new system offers certain advantages over computer-controlled systems described previously for continuous infusion of muscle relaxants--that is, the option to choose either of two muscle relaxants to be infused and the inclusion of monitors to provide feedback about the dosage needed to produce a target level of neuromuscular blockade."( A versatile, computer-controlled, closed-loop system for continuous infusion of muscle relaxants.
Assef, SJ; Behrens, TL; Burke, MJ; Jones, KA; Lennon, RL, 1993
)
0.29
" We found that atracurium was prescribed for 68% of study patients; 68% of the patients did not have renal, hepatic, or cardiovascular disease; dosages of NNMBAs varied; a statistically significant increase in dosage requirements over time occurred with atracurium; assessment of neuromuscular blockade was 100% subjective; and 41% and 17% of patients receiving atracurium and vecuronium, respectively, experienced prolonged neuromuscular weakness documented subjectively."( A retrospective analysis of long-term use of nondepolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection.
Clarens, DM; Gilliland, SS; Kelly, KJ; Kohls, PK; Nahum, A; Vance-Bryan, K,
)
0.48
" For groups 2 and 6, atracurium was administered at a dosage of 4 mg/kg of body weight, followed by a continuous infusion of 15 mg/kg/h."( Porphyrinogenic effects of atracurium, vecuronium, and pancuronium in a primed rat model.
Bach, A; Böhrer, H; Bolsen, K; Goerz, G; Kohl, B; Martin, E; Schmidt, H, 1994
)
0.9
" The dose-response relationships of atracurium, mivacurium and their combination were studied in 96 ASA I or II patients during thiopentone-fentanyl-nitrous oxide-isoflurane (1."( Interactions between mivacurium and atracurium.
Abdulatif, M; al-Ghamdi, A; el-Sanbary, M; Magboul, MA; Naguib, M; Selim, M; Seraj, M, 1994
)
0.84
"In patients with extreme stature or build, estimation of individual dosage requirements of muscle relaxants by body weight is unreliable."( [Dose-response relationship of atracurium in underweight, normal and overweight patients].
Blobner, M; Felber, AR; Jelen-Esselborn, S; Schneck, HJ, 1994
)
0.57
" We have studied 57 patients undergoing gynaecological surgery to establish a dose-response relationship when neostigmine was given to antagonize atracurium-induced block."( Optimum dose of neostigmine at two levels of atracurium-induced neuromuscular block.
Hall, IA; Harper, NJ; Wallace, M, 1994
)
0.75
"05 mg/kg at 3-minute intervals to establish approximately 95% twitch inhibition so as to construct a dose-response curve."( The effect of ondansetron on atracurium-induced neuromuscular blockade.
Embree, PB; Gadalla, F; Kudlak, TT; Lien, CA; Savarese, JJ; Sharp, GJ,
)
0.42
"Log dose-response curves were determined for the study groups and compared using analysis of variance (ANOVA)."( The effect of ondansetron on atracurium-induced neuromuscular blockade.
Embree, PB; Gadalla, F; Kudlak, TT; Lien, CA; Savarese, JJ; Sharp, GJ,
)
0.42
"To describe a previously unreported event in which a patient became refractory to atracurium-induced neuromuscular blockade, but subsequently was adequately paralyzed with a standard dosage of pancuronium."( Response to pancuronium after loss of atracurium-induced neuromuscular blockade.
Clarens, DM; Kelly, KJ; Kohls, PR; Nahum, A; Vance-Bryan, K,
)
0.63
"The aim of our randomized controlled study was to compare the neuromuscular characteristics of mivacurium and atracurium by evaluating the intubation conditions, intubation times, onset times and the duration of action of these two muscle relaxants using two different dosing principles."( [Comparison of neuromuscular blockade by mivacurium and atracurium].
Benad, G; Hofmockel, R; Jantschulev, S, 1995
)
0.75
" This change was reflected in a shift of the dose-response curve to the right in the pretreated rats."( Resistance to atracurium in rats with experimental inflammation: role of protein binding.
Calvo, R; García, E; Jiménez, R; Rodríguez-Sasiaín, JM; Suárez, E; Trocóniz, IF, 1995
)
0.65
"We have compared the dose-response relationships of suxamethonium, mivacurium and atracurium and examined the interactions of suxamethonium with mivacurium or atracurium in humans by isobolographic analysis."( Interactions between suxamethonium and mivacurium or atracurium.
Chon, SU; Kim, KS; Na, DJ, 1996
)
0.77
" The technique used and the dosage of drugs, introduced by infusion, are described."( [Propofol (Diprivan) in emergency anesthesia].
Aluan, K; Badeva, B; Bochev, D; Giurova, Z; Petrov, P; Vankov, I, 1996
)
0.29
" In these patients appropriate dosing of muscle relaxants and adequate monitoring of the neuromuscular blockade are required."( Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy.
Bittner, R; Finsterer, J; Sporn, P; Stratil, U, 1998
)
0.57
"We compared the dose-response relationships of cisatracurium, mivacurium, atracurium, vecuronium and rocuronium and examined the interactions of cisatracurium with mivacurium, atracurium, vecuronium and rocuronium in humans by isobolographic and fractional analyses."( Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or rocuronium administered in combination.
Chon, SU; Chun, YS; Kim, KS; Suh, JK, 1998
)
0.83
"To prospectively evaluate the efficacy and dosage requirements of cis-atracurium administered by continuous infusion for neuromuscular blockade in a pediatric intensive care unit population."( A prospective evaluation of the continuous infusion of cis-atracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements.
Tobias, JD,
)
0.61
" The dose-response relationship of atracurium was determined by a cumulative dose-response technique."( Influences of age and gender on dose response and time course of effect of atracurium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Xue, FS; Zhang, YM, 1999
)
0.81
" Age and gender significantly affected the dose-response relationship and time course of recovery of atracurium."( Influences of age and gender on dose response and time course of effect of atracurium in anesthetized adult patients.
An, G; Liao, X; Liu, JH; Xue, FS; Zhang, YM, 1999
)
0.75
"We have compared the dose-response relationship (n = 30) and time course of neuromuscular block (n = 20) of cisatracurium at the laryngeal adductor and the adductor pollicis muscles."( Cisatracurium neuromuscular block at the adductor pollicis and the laryngeal adductor muscles in humans.
Chung, CW; Kim, KS; Shin, WJ, 1999
)
1.14
" The aim of this study was to evaluate the influence of acute isovolaemic haemodilution on the dose-response and time-course of action of atracurium."( Influence of acute normovolaemic haemodilution on the dose-response and time-course of action of atracurium.
An, G; Liao, X; Liu, JH; Luo, LK; Xue, FS; Zhang, YM, 2000
)
0.73
" The dose-response relationships of atracurium in the two groups were determined by the cumulative dose-response technique."( Influence of acute normovolaemic haemodilution on the dose-response and time-course of action of atracurium.
An, G; Liao, X; Liu, JH; Luo, LK; Xue, FS; Zhang, YM, 2000
)
0.8
"The results showed that during haemodilution, the dose-response curve of atracurium was shifted to the left in a parallel fashion and the potency of atracurium was increased."( Influence of acute normovolaemic haemodilution on the dose-response and time-course of action of atracurium.
An, G; Liao, X; Liu, JH; Luo, LK; Xue, FS; Zhang, YM, 2000
)
0.76
"To study the dose-response relationships for neostigmine and edrophonium during antagonism of neuromuscular block induced by atracurium and cisatracurium."( Dose-response relationships for edrophonium and neostigmine antagonism of atracurium and cisatracurium-induced neuromuscular block.
Naguib, M; Riad, W, 2000
)
0.74
" Potency and efficacy were derived from nonlinear fittings of the dose-response curves."( Different patterns of mast cell activation by muscle relaxants in human skin.
Blunk, JA; Koppert, W; Petersen, LJ; Rentsch, K; Schmelz, M; Skov, P, 2001
)
0.31
"For succinylcholine and the isoquinolines, dose-response curves for the vascular and sensory effects paralleled the histamine and tryptase release."( Different patterns of mast cell activation by muscle relaxants in human skin.
Blunk, JA; Koppert, W; Petersen, LJ; Rentsch, K; Schmelz, M; Skov, P, 2001
)
0.31
"To compare the characteristics of the dose-response relationship and the time course of action between atracurium and rocuronium in adult patients anesthetized with N2O-O2-fentanyl-thiopene."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.75
" The dose-response relationship of atracurium and rocuronium was determined by the cumulative dose-response technique."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.82
"According to the dose-response curves established by a least squares linear regression, the potency ratio of atracurium to rocuronium was 1:1."( A comparative study of the dose-response and time course of recovery of atracurium and rocuronium.
An, G; Liao, X; Liu, J; Xue, F; Zhang, Y, 2000
)
0.75
"Pharmacodynamic studies of muscle relaxants use different dosing regimens (such as administration by bolus vs."( Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
Fisher, DM; Paul, M, 2002
)
0.31
"To compare dosing requirements over time among patients receiving continuous cisatracurium versus pancuronium therapy, and to identify factors that may account for changes in pancuronium versus cisatracurium infusion requirements over time."( Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy.
Barletta, JF; Devlin, JW; Janisse, JJ; Kanji, S; Kruse, JA, 2002
)
0.8
" Factors that could affect dosing requirements of a neuromuscular blocking agent (NMBA) were stratified as time invariant (admitting service, acute physiology and chronic health evaluation II score, duration of mechanical ventilation, pressure control ventilation, baseline hepatic or renal insufficiency, thermal injury, train-of-four assessment, and concurrent drug administration or disorders affecting neuromuscular transmission) or time variant (concurrent sedation and narcotic analgesia therapy; serum magnesium, potassium, and creatinine concentrations; arterial pH level; temperature; peak airway pressure; and partial pressure of oxygen:fraction of inspired oxygen ratio)."( Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy.
Barletta, JF; Devlin, JW; Janisse, JJ; Kanji, S; Kruse, JA, 2002
)
0.58
"01), but was not associated with differences in atracurium dosage or a reduction in PORC at extubation."( Atracurium is associated with postoperative residual curarization.
Boylan, JF; McCaul, C; McShane, AJ; Tobin, E, 2002
)
2.01
"To evaluate the influences of age and sex on dose-response and recovery time course of atracurium."( [Influences of age and gender on dose-response and recovery time-course of atracurium].
An, G; He, N; Liao, X; Xue, FS; Zhang, YM, 2001
)
0.76
" The dose-response relations of atracurium were determined by the cumulative dose-response technique."( [Influences of age and gender on dose-response and recovery time-course of atracurium].
An, G; He, N; Liao, X; Xue, FS; Zhang, YM, 2001
)
0.82
"As compared to older and female patients, dose-response curves of atracurium in young and male patients were shifted in a parallel fashion to the left."( [Influences of age and gender on dose-response and recovery time-course of atracurium].
An, G; He, N; Liao, X; Xue, FS; Zhang, YM, 2001
)
0.78
" However, delayed onset time, non-linearity of the dose-response curve and different sensitivity to muscle relaxants for each patient are limiting factors."( [Feedback control of muscle relaxation with a varying on-off controller using cisatracurium].
Hofmockel, R; Lampe, BP; Pohl, B; Simanski, O; Wende, K, 2004
)
0.55
" The dose-response effect measured at both muscles included maximum neuromuscular blockade achieved (Emax), the time to maximum depression of twitch height (onset) and time to spontaneous recovery of the twitch height to 25%, 75% and 90% (T25, T75, T90) of control value."( Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor pollicis.
Behforouz, N; Decailliot, F; Duvaldestin, P; Kirov, K; Motamed, C, 2004
)
0.57
" In conclusion, the duration of action of cisatracurium was prolonged in morbidly obese patients when dosed according to RBW compared with a control group of normal weight patients."( The effects of cisatracurium on morbidly obese women.
Gullo, A; Leykin, Y; Lomangino, G; Lucca, M; Marzano, B; Pellis, T, 2004
)
0.92
" No significant differences were noted between TOF monitoring and clinical assessment in mean total paralysis time (4,118 +/- 1,012 min vs 3,188 +/- 705 min, respectively), mean total cisatracurium dose (920 +/- 325 mg vs 715 +/- 167 mg), or dosage (2."( A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis.
Ahmad, I; Baumann, MH; Brown, K; McAlpin, BW; Patel, P; Petrini, M; Stewart, R, 2004
)
0.73
"TOF monitoring does not lead to improved recovery time or lower cisatracurium dosing compared with monitoring by clinical assessment."( A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis.
Ahmad, I; Baumann, MH; Brown, K; McAlpin, BW; Patel, P; Petrini, M; Stewart, R, 2004
)
0.77
" That information was used to estimate the mean potency for each individual by an alternative method based on prior knowledge of the slope of the dose-response curve."( [Interaction between vecuronium and atracurium revisited by adapting an alternative method].
Steinberg, D, 2004
)
0.6
" Increasing magnesium dosage did not offer any advantages, but induced haemodynamic consequences."( Effects of three different dose regimens of magnesium on propofol requirements, haemodynamic variables and postoperative pain relief in gynaecological surgery.
Akpir, K; Kayacan, S; Pembeci, K; Seyhan, TO; Sungur, MO; Telci, L; Tugrul, M, 2006
)
0.33
"Using the Relaxometer mechanomyograph, we compared cisatracurium dose-response relationship and time course of action in 60 patients randomly allocated to the ANH or control groups."( Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate.
Bornemann, H; Dahaba, AA; Liu, X; Metzler, H; Wang, G; Wu, X; Xu, X, 2007
)
0.8
"ANH did not result in a significant shift in cisatracurium log dose-probit dose-response curve."( Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate.
Bornemann, H; Dahaba, AA; Liu, X; Metzler, H; Wang, G; Wu, X; Xu, X, 2007
)
0.81
"The authors found no study comparing potency and duration of action of vecuronium and atracurium in healthy Chinese, so they compared the dose-response relations of vecuronium and atracurium in anesthetized Chinese adult patients and evaluated the time-course of action of two drugs following administration of equipotent doses."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.79
" The dose-response relations of vecuronium and atracurium were determined using the cumulative dose-response technique."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.83
"The cumulative dose-response curve of vecuronium was shifted to the left in a parallel fashion compared with that of atracurium."( Comparisons of the dose-response and recovery time course of vecuronium and atracurium in anesthetized chinese adult patients.
Li, CW; Li, P; Liao, X; Liu, KP; Liu, Y; Sun, HT; Xu, YC; Xue, FS, 2007
)
0.78
" The two groups were evaluated for time of alertness and extubation in the intensive care unit, total analgesic dosage administered during the 24 hours after operation, arterial blood gas and peripheral saturation of oxygen before and after extubation."( Fast-track method in cardiac surgery: evaluation of risks and benefits of continuous administration technique.
Najafi, M, 2008
)
0.35
" At this time, the dose-response curve for atracurium on the immobilized side was shifted to the left in the pyridostigmine group."( Continuous administration of pyridostigmine improves immobilization-induced neuromuscular weakness.
Blobner, M; Fink, H; Frick, CG; Helming, M; Martyn, JA, 2010
)
0.62
" Some statisticians now consider this approach outmoded and assert that non-linear regression (NLR) is the preferred way to analyse sigmoidal dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.36
"We analysed raw data for succinylcholine, rocuronium, rapacuronium, and cisatracurium from previously published studies using both LRA and NLR to determine the ED(50) and ED(95) values and the respective slopes of the dose-response relationships."( Determining the potency of neuromuscular blockers: are traditional methods flawed?
Kopman, AF; Lien, CA; Naguib, M, 2010
)
0.59
" Dosing of atracurium based on lean body mass, total body weight, and total body weight with a dose reduction for every 10 kg more than 70 kg have been proposed."( Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients.
Diepstraten, J; Knibbe, CA; van de Garde, EM; van Dongen, EP; van Kralingen, S; van Ramshorst, B; Wiezer, MJ, 2011
)
1.06
" A dose-dependent prolongation of action is shown when dosing is based on total body weight."( Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients.
Diepstraten, J; Knibbe, CA; van de Garde, EM; van Dongen, EP; van Kralingen, S; van Ramshorst, B; Wiezer, MJ, 2011
)
0.67
"This double-blind randomized study evaluated atracurium dosing based on ideal body weight vs."( Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients.
Diepstraten, J; Knibbe, CA; van de Garde, EM; van Dongen, EP; van Kralingen, S; van Ramshorst, B; Wiezer, MJ, 2011
)
0.93
" A dose-dependent prolongation of action is shown when dosing is based on total body weight."( Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients.
Diepstraten, J; Knibbe, CA; van de Garde, EM; van Dongen, EP; van Kralingen, S; van Ramshorst, B; Wiezer, MJ, 2011
)
0.67
" The aim of our study was to compare dose-response and time-course-of-action of cisatracurium besylate, an NMBA eliminated via the Hoffman degradation, in two countries with different life habits, diet, and ambient conditions; being Han Chinese in China and Caucasians in Bosnia."( No regional difference in cisatracurium dose-response and time-course-of-action between patients in China and Bosnia.
Bornemann, H; Dahaba, AA; Metzler, H; Suljevic, I; Wu, XM, 2011
)
0.89
" Dose-response curves were created using log-dose-probit-response transformation."( No regional difference in cisatracurium dose-response and time-course-of-action between patients in China and Bosnia.
Bornemann, H; Dahaba, AA; Metzler, H; Suljevic, I; Wu, XM, 2011
)
0.66
"Cisatracurium dose-response relationship and time-course-of-action were not influenced by geographic location."( No regional difference in cisatracurium dose-response and time-course-of-action between patients in China and Bosnia.
Bornemann, H; Dahaba, AA; Metzler, H; Suljevic, I; Wu, XM, 2011
)
1.28
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" According to log-probit transformation of the data of the dose and response, the dose-response curve of cisatracurium was established through linear regression."( [Impact of gender on the dose-effect relationship of cisatracurium].
Liang, QB; Shi, HJ, 2011
)
0.83
"This study suggests that standard dosing of cisatracurium in patients with severe sepsis results in a slower patient response with a reduced effect."( The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis.
Kruger, PS; Liu, X; Roberts, MS; Weiss, M, 2012
)
0.89
" Pulmonary function tests were performed before and after neuromuscular blocking drug dosing and again after albuterol administration."( The effect of cisatracurium and rocuronium on lung function in anesthetized children.
Fine, GF; Jooste, EH; Motoyama, EK; Mutich, R; Walczak, SA; Yang, CI, 2013
)
0.73
" The propofol dosage required for anesthetic maintenance was 29% (with a 95% confidence interval, 18-40) lower in patients given dexmedetomidine (2."( Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial.
Augé, M; Bonnet, F; Chazot, T; Dardelle, D; Fischler, M; Laloë, PA; Le Guen, M; Liu, N; Sessler, DI; Tounou, F; Tuil, O, 2014
)
0.4
" The physicochemical stability was assessed at 24, 48hours and seven days with dosage of the active substance, detection of degradation products and a possible racemization, measuring pH, osmolality and turbidity, assessment of coloration, visible particles and invisible particles count."( [Physicochemical stability study of injectable solutions of cisatracurium besilate in clinical conditions].
Bourdeaux, D; Constantin, JM; Kauffmann, S; Pignard, J; Sautou, V, 2014
)
0.64
"To explore the neuromuscular effects of cisatracurium besylate in morbidly obese patients when dosed according to real body weight under total intravenous anesthesia with propofol."( [Neuromuscular effects of cisatracurium besylate in obese patients].
Geng, Z; Wu, X, 2014
)
0.96
"When dosed according to real body weight, onset time of cisatracurium is shorter while clinical duration and recovery index are prolonged in morbidly obese patients compared with normal weight counterparts."( [Neuromuscular effects of cisatracurium besylate in obese patients].
Geng, Z; Wu, X, 2014
)
0.94
"The dose-response relationship of drugs to reverse vecuronium-, rocuronium-, and cisatracurium-induced neuromuscular block (NMB) was evaluated in vitro (competition binding assays and urine analysis), ex vivo (n = 34; phrenic nerve hemidiaphragm preparation), and in vivo (n = 108; quadriceps femoris muscle of the rat)."( Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.
Ayata, C; Blobner, M; Diaz-Gil, D; Eikermann, M; Eikermann-Haerter, K; Foerster, U; Ganapati, S; Haerter, F; Isaacs, L; Moreno Duarte, I; Simons, JC; Zhang, B, 2015
)
0.64
"In addition, the data were also gathered on the dosage of ephedrine and atropine were used, as well as the intraoperative awareness in the patients who were followed up on the first day after the operation."( [Impact of dexmedetomidine-sevoflurane anesthesia on intraoperative wake-up test in children patients undergoing scoliosis surgery].
An, HX; Quan, LX; Wang, DX, 2016
)
0.43
" The time of muscle relaxation recovery was shortened, the dosage of cisatracurium was reduced, and the number of cases of insufficient muscle relaxation was reduced."( Comparative study: efficacy of closed-looptarget controlled infusion of cisatracurium and other administration methods for spinal surgery of elderly patients.
Dai, BZ; Du, SY; Kong, DQ; Li, BP; Ma, XD; Yan, J, 2017
)
0.92
"When using cisatracurium under AHH, the dosage should be increased appropriately, while it need not be adjusted under ANH."( Pharmacokinetics and pharmacodynamics of cisatracurium in patients undergoing surgery with two hemodilution methods.
Guo, J; Jin, X; Yuan, X; Zhou, X, 2017
)
1.08
" The goal of our study was to investigate the real-world practice pattern of dosing of neuromuscular blocking agents (NMBA), utilizing the amount of NMBA used during the course of a case, adjusted for patient weight and case duration, as a surrogate measure of depth of NMB."( Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
Beutler, SS; Gimlich, R; Palsen, S; Urman, RD; Wu, A; Yang, HK, 2019
)
0.51
" Cis-atracurium is a benzylisoquinolinium neuromuscular blocking agent with an intermediate duration of action devoid of significant adverse effects previously used in pigs with a wide dosage range."( Neuromuscular block monitoring after the administration of 1 mg/kg intravenous cis-atracurium in the anaesthetized pig.
Aguilar, A; Andaluz, A; García, F; Moll, X, 2019
)
1.25
"A case report involving varying cisatracurium dosing requirements in a hyperthermic patient undergoing prone ventilation who subsequently received active cooling as part of targeted temperature management is presented."( Cisatracurium dosing in a patient with hyperthermia.
Arya, R; Cox, J; Lim, J; Nguyen, T, 2019
)
1.41
" Previous reports in the literature described cases of decreased dosing requirements for both cisatracurium and its parent compound, atracurium, for patients in hypothermic states."( Cisatracurium dosing in a patient with hyperthermia.
Arya, R; Cox, J; Lim, J; Nguyen, T, 2019
)
1.35
"Neuromuscular blockade (NMB) with cisatracurium may improve outcomes in the acute respiratory distress syndrome (ARDS) population; however, optimal dosing strategy remains unknown."( Predictors of Cisatracurium Continuous Infusion Dose in Acute Respiratory Distress Syndrome.
Bellamy, C; Candeloro, C; Fuchs, B; Massey, K; Merkel, A; Miano, T, 2021
)
1.23
" However, the cis-atracurium dosage for laryngeal mask insertion has not been standardised."( The median effective dose (ED50) of cis-Atracurium for laryngeal mask airway insertion during general Anaesthesia for patients undergoing urinary surgery.
Huang, K; Lan, F; Li, Y; Wang, T; Wang, X; Xue, J; Yan, H; Yao, D, 2020
)
1.16
" Further investigations are necessary to determine the safe dosage of volatile anesthetics specifically for this clinical scenario so that anesthesiologists can use this combination method more accurately and precisely."( Laparoscopic gynecological surgery in an adult woman with Becker muscular dystrophy performed with sevoflurane with cisatracurium anesthesia: A case report.
Liu, C; Ma, HC; Shan, BL; Wang, D; Zhang, S; Zhou, SY, 2020
)
0.77
" We compared clinical monitoring alone or with TOF monitoring to guide atracurium dosage adjustment with respect to drug dose and respiratory parameters."( Neuromuscular Blockade Monitoring in Acute Respiratory Distress Syndrome: Randomized Controlled Trial of Clinical Assessment Alone or With Peripheral Nerve Stimulation.
Amaru, P; Genty, T; Imbert, A; Laverdure, F; Pilorge, C; Rezaiguia-Delclaux, S; Sarfati, C; Stéphan, F, 2021
)
0.85
"To compare the optimal dosage and safety of neostigmine for reversing shallow residual block in elderly patients after cisatracurium-induced neuromuscular block."( Optimal dose of neostigmine antagonizing cisatracurium-induced shallow neuromuscular block in elderly patients: a randomized control study.
Cao, M; Huang, H; Liao, Y; Ou, Y; Tong, J, 2023
)
1.38
"9, among which 40 µg/kg dosage may be a more optimized choice."( Optimal dose of neostigmine antagonizing cisatracurium-induced shallow neuromuscular block in elderly patients: a randomized control study.
Cao, M; Huang, H; Liao, Y; Ou, Y; Tong, J, 2023
)
1.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
muscle relaxantA drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
nicotinic antagonistAn antagonist at the nicotinic cholinergic receptor.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
quaternary ammonium ionA derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
diesterA diester is a compound containing two ester groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Small conductance calcium-activated potassium channel protein 3Rattus norvegicus (Norway rat)Ki5.90000.00182.13265.9000AID346945
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NPYLR7BAedes aegypti (yellow fever mosquito)EC50 (µMol)20.00000.03902.289918.3000AID1259426
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Kd6.40000.00271.66496.4000AID346946
Small conductance calcium-activated potassium channel protein 3Rattus norvegicus (Norway rat)Kd6.40000.00271.66496.4000AID346946
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID219534Dose causing 50% block of muscle twitch in isolated chick biventer cervicis muscle (Decrease in baseline tension)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID346946Inhibition of Wistar rat recombinant SK3 channel expressed in HEK293 cells by whole cell patch clamp technique2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators ofsmall conductance Ca2+-activated K+ channels.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID219386Inhibition of superior cervical nerve-induced contractions of the nictitating membrane in anesthetized cats; ND means no data2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID219390Onset time was measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID346945Displacement of [I125]apamine from Wistar rat recombinant SK3 channel expressed in HEK293 cells2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators ofsmall conductance Ca2+-activated K+ channels.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID241212Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes2004Bioorganic & medicinal chemistry letters, Aug-02, Volume: 14, Issue:15
Defining determinant molecular properties for the blockade of the apamin-sensitive SKCa channel in guinea-pig hepatocytes: the influence of polarizability and molecular geometry.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219389Duration (90%) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219378Inhibition of stimulated vagus nerve-induced bradycardia in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID21877Calculated partition coefficient (clogP)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219382Inhibitory potency in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219391Recovery time (25-75 %) measured for NMB activity in anesthetized cats2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Non-depolarizing neuromuscular blocking activity of bisquaternary amino di- and tripeptide derivatives.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346570Human nicotinic acetylcholine receptor alpha3 subunit (Nicotinic acetylcholine receptors)2006Anesthesiology, Sep, Volume: 105, Issue:3
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
AID1346547Human nicotinic acetylcholine receptor alpha4 subunit (Nicotinic acetylcholine receptors)2006Anesthesiology, Sep, Volume: 105, Issue:3
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
AID1346623Human nicotinic acetylcholine receptor alpha1 subunit (Nicotinic acetylcholine receptors)2006Anesthesiology, Sep, Volume: 105, Issue:3
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
AID1346583Human nicotinic acetylcholine receptor alpha7 subunit (Nicotinic acetylcholine receptors)2006Anesthesiology, Sep, Volume: 105, Issue:3
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
AID1799782Inhibitor Screening Assay from Article 10.1074/jbc.M109.039511: \\Inhibition of AcpA phosphatase activity with ascorbate attenuates Francisella tularensis intramacrophage survival.\\2010The Journal of biological chemistry, Feb-19, Volume: 285, Issue:8
Inhibition of AcpA phosphatase activity with ascorbate attenuates Francisella tularensis intramacrophage survival.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,822)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990595 (32.66)18.7374
1990's578 (31.72)18.2507
2000's361 (19.81)29.6817
2010's221 (12.13)24.3611
2020's67 (3.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.23 (24.57)
Research Supply Index7.83 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index125.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials561 (28.81%)5.53%
Reviews71 (3.65%)6.00%
Case Studies318 (16.33%)4.05%
Observational18 (0.92%)0.25%
Other979 (50.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (50)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery [NCT01147146]64 participants (Actual)Interventional2010-06-30Completed
Bilateral Transversus Abdominis Plane Block Versus Atracurium During Laparoscopic Gynecology Procedures. Do we Really Still Need the Systemic Neuromuscular Blocking Agents? [NCT03701256]Phase 4100 participants (Actual)Interventional2015-02-01Completed
ED50 of Cis-atracurium for Laryngeal Mask Incubation in General Anesthesia During Urology Surgery [NCT03668262]35 participants (Actual)Observational [Patient Registry]2018-09-15Completed
Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting [NCT06102915]289 participants (Actual)Observational2023-08-01Completed
The Impact of Using Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway (LMA) Insertion on Hemodynamics and Induction Anesthetics Dosage in Elderly [NCT05310110]200 participants (Anticipated)Interventional2022-04-12Recruiting
Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study [NCT02224443]Phase 490 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Efficacy and Safety of Low Dose Atracurium Added to Lidocaine, Bupivacaine and Hyaluronidase Mixture in Percaruncular Peribulbar Anesthesia for High Myopes Undergoing Phacoemulsification: A Randomized Controlled Trial. [NCT03243500]Phase 491 participants (Actual)Interventional2015-05-01Completed
[NCT02404142]Phase 464 participants (Actual)Interventional2015-02-20Completed
Effect of Atracurium and Rocuronium on the State and Response Entropy During Isoflurane Anesthesia [NCT05097508]Early Phase 140 participants (Actual)Interventional2020-06-20Completed
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients [NCT01097148]Phase 420 participants (Actual)Interventional2009-11-30Completed
Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake Up-single Center,Random,Controlled Trial [NCT02143362]Phase 460 participants (Anticipated)Interventional2014-06-30Not yet recruiting
Three-level Injection Paravertebral Block Using Paravertebral Catheter Compared to General Anesthesia in Mastectomy Surgery [NCT02065947]Phase 1/Phase 260 participants (Actual)Interventional2013-10-31Completed
A Randomized Controlled Trial: Role of EFTs (Emotional Freedom Techniques) in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy. [NCT02169856]50 participants (Actual)Interventional2013-07-31Completed
Respiratory Benefits of Small Doses Muscle Relaxant in General Anesthesia [NCT04344262]60 participants (Anticipated)Interventional2020-04-22Recruiting
Standardised Drug Provocation Testing in Perioperative Hypersensitivity [NCT06065137]Phase 450 participants (Anticipated)Interventional2023-10-31Not yet recruiting
A Randomized, Parallel Design, Single-center Study to Compare of Surgical Condition and Postoperative Complications With Moderate and Deep Neuromuscular Blockade in Laparoscopic Gastrectomy [NCT02601508]80 participants (Anticipated)Interventional2015-11-30Not yet recruiting
Ultrasound-Guided Bilateral Pecto-intercostal Fascial Block Versus Intravenous Fentanyl for Postoperative Pain Management After Pediatric Cardiac Surgery A Prospective, Randomized, Controlled Study [NCT04945694]80 participants (Anticipated)Interventional2021-08-31Not yet recruiting
Perioperative Cardiovascular Protection Conservative Effects of Esketamine Versus µ-opioid Receptor Agonists in Total Intravenous General Anesthesia: Study Protocol for a Randomized Controlled Pilot Trial [NCT04553536]1,000 participants (Anticipated)Interventional2020-11-02Recruiting
The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia [NCT00910416]40 participants (Actual)Observational2009-05-31Terminated(stopped due to Differences between BIS and Neurosense are important. This study can be terminated.)
Effect of Dexmedetomidine Infusion on Desflurane Consumption and Hemodynamics During BIS Guided Laparoscopic Surgery: A Randomized Controlled Study [NCT02652312]40 participants (Actual)Interventional2016-02-29Completed
Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction [NCT02546843]66 participants (Actual)Interventional2015-12-31Completed
Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy [NCT02162134]90 participants (Actual)Interventional2013-01-31Completed
Controlled Hypotension During Endoscopic Sinus Surgery: A Comparison of Propofol and Magnesium Sulfate [NCT04078659]50 participants (Anticipated)Interventional2019-09-30Not yet recruiting
Effect of Magnesium Sulphate Pretreatment on the Onset and Duration of Intense and Deep Neuromuscular Block of Rocuronium Versus Cis-Atracurium in Pediatric Laparoscopic Surgery [NCT05736744]Phase 2/Phase 358 participants (Anticipated)Interventional2023-03-20Not yet recruiting
Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome [NCT05153525]Phase 460 participants (Anticipated)Interventional2022-01-06Recruiting
A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery [NCT03005860]0 participants (Actual)Interventional2017-01-01Withdrawn(stopped due to Funding could not be arranged, so the study was prematurely terminated)
Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery: Effect on Postoperative Pain and Opioid Consumption [NCT02544282]Phase 4140 participants (Actual)Interventional2014-04-30Completed
Post-arrest Therapeutic Hypothermia. Does Use of Neuromuscular Blockers Achieve Faster Cooling Time? [NCT02033733]400 participants (Anticipated)Observational2014-01-31Not yet recruiting
Cerebral NIRS Profiles During Premedication for Neonatal Intubation [NCT02700893]Phase 2/Phase 328 participants (Actual)Interventional2016-03-31Completed
Comparison of Local Anesthesia and Induced Hypotensive Anesthesia on Quality of External Dacryocystorhinostomy Operation Under General Anesthesia [NCT05241054]64 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Atracurium Mixed With Magnesium Sulfate Versus Atracurium Alone as Adjuvant to Lidocaine in Intravenous Regional Anesthesia [NCT02920905]Phase 375 participants (Actual)Interventional2015-11-30Completed
Assessment of Ultrasonographic Carotid Artery Corrected Flow Time and Internal Jugular Vein Collapsibility Index in Prediction of Hypotension During Induction of General Anesthesia [NCT06078228]70 participants (Anticipated)Observational [Patient Registry]2023-09-24Enrolling by invitation
Intranasal Premedication With Dexmedetomidine Versus Intravenous Dexmedetomidine for Hypotensive Anesthesia During Functional Endoscopic Sinus Surgery in Adults: A Randomized Triple-Blind Trial [NCT05604599]Phase 460 participants (Actual)Interventional2022-11-10Completed
Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients [NCT00299650]Phase 4340 participants (Anticipated)Interventional2006-03-31Completed
Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol [NCT05533567]12 participants (Anticipated)Interventional2022-10-01Recruiting
Study of Effects of Cisatracurium and Atracurium on Intraocular Pressure [NCT01273831]Phase 290 participants (Actual)Interventional2009-07-31Completed
A Comparative Study of Analgesic Effect of Ultrasound Guided Erector Spinae Plane Block Versus Quadratus Lumborum Block for Open Colorectal Cancer Surgeries [NCT03803267]68 participants (Actual)Interventional2019-05-01Completed
Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial [NCT02495038]81 participants (Actual)Interventional2014-03-31Completed
Early Versus Late Paravertebral Block for Analgesia in Video Assisted Thoracoscopic Lung Resection. [NCT01621698]100 participants (Anticipated)Interventional2012-07-31Completed
Effect of Dexmedetomidine on Cisatracurium Infusion and Sufentanil Consumption and Its Variations in Different Age Groups, Using a Closed Loop Computer Controlled System. [NCT01785446]150 participants (Anticipated)Interventional2012-11-30Recruiting
Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery. [NCT01631149]Phase 424 participants (Actual)Interventional2012-06-30Completed
The Comparison of Different Administration Routes of Pediatric Premedication-Single Center,Randomized,Controlled Trial [NCT02313337]Phase 480 participants (Anticipated)Interventional2014-12-31Not yet recruiting
Efficacy of Atracurium-vecuronium Combination in Patients Undergoing Laparoscopic Surgery:a Randomised Controlled Study [NCT03371953]Phase 448 participants (Anticipated)Interventional2017-12-20Not yet recruiting
Awakening in Spine Surgery Patients Having Neurophysiologic Monitoring: A Comparison Study Between Clinical Signs and Bispectral Index (BIS) Guided Target Controlled Infusion(TCI) of Propofol [NCT02174913]34 participants (Actual)Interventional2014-05-31Completed
Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS [NCT01573715]Phase 440 participants (Anticipated)Interventional2012-04-30Recruiting
Quadratus Lumborum Versus Transversus Abdominis Plane Block Versus Caudal Block for Postoperative Analgesia After Pediatric Inguinal Hernia : Double-Blinded Randomized Trial [NCT05442905]60 participants (Anticipated)Interventional2022-08-01Not yet recruiting
Differential Effects of Remimazolam and Propofol on Dynamic Cerebral [NCT05533580]50 participants (Anticipated)Interventional2022-10-01Recruiting
"Double Blind Randomized Controlled Trial Comparing Atropine+Propofol Versus Atropine+Atracurium+Sufentanil as a Premedication Prior to Semi-urgent or Elective Endotracheal Intubation of Term and Preterm Newborns" [NCT01490580]Phase 2/Phase 3173 participants (Actual)Interventional2012-05-31Completed
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period [NCT02518789]Phase 4132 participants (Anticipated)Interventional2015-09-30Not yet recruiting
[NCT02109133]67 participants (Actual)Interventional2014-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01490580 (8) [back to overview]Duration of Intubation Procedure
NCT01490580 (8) [back to overview]Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2
NCT01490580 (8) [back to overview]Number of Patients With Prolonged Desaturation
NCT01490580 (8) [back to overview]Short Term Neurological Outcome: Worsening of Head Ultrasound
NCT01490580 (8) [back to overview]Heart Rate
NCT01490580 (8) [back to overview]Mean Blood Pressure
NCT01490580 (8) [back to overview]Pulse Oxymetry
NCT01490580 (8) [back to overview]Transcutaneous PCO2 (TcPCO2) Measurement
NCT01631149 (5) [back to overview]Breathing
NCT01631149 (5) [back to overview]Nausea and Vomiting
NCT01631149 (5) [back to overview]Post-operative Pain
NCT01631149 (5) [back to overview]Postoperative Sedation Score
NCT01631149 (5) [back to overview]Surgical Rating Scale
NCT02109133 (4) [back to overview]Incidence of Residual Neuromuscular Blockade
NCT02109133 (4) [back to overview]Maximum Intraocular Pressure During RALRP Under Deep Neuromuscular Blockade
NCT02109133 (4) [back to overview]Overall Surgical Condition
NCT02109133 (4) [back to overview]Post-operative Nausea
NCT02174913 (2) [back to overview]Extubation Time
NCT02174913 (2) [back to overview]Total Propofol Dosage
NCT02495038 (10) [back to overview]Additional Rescue Doses Per Hour Ratio.
NCT02495038 (10) [back to overview]Anesthetic Time
NCT02495038 (10) [back to overview]Bispectral Index
NCT02495038 (10) [back to overview]Body Temperature
NCT02495038 (10) [back to overview]Duration 25% of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Onset of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Operation Time
NCT02495038 (10) [back to overview]Peripheral Oxygen Saturation
NCT02495038 (10) [back to overview]Recovery Index of Neuromuscular Blocking Agents(NMBAs)
NCT02495038 (10) [back to overview]Non Invasive Blood Pressure,

Duration of Intubation Procedure

Although the initial definition of procedure duration in the registered protocol was the time between the first laryngoscope insertion and last laryngoscope removal after successful intubation, the variable collected in the clinical research form was defined as the time between first laryngoscope insertion and the fixation of the tube with tape. (NCT01490580)
Timeframe: Expected duration 1 to 15 minutes

InterventionMinutes (Median)
Atropine + Propofol6.0
Atropine + Atracurium + Sufentanil3.5

[back to top]

Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2

Survival without risk of neurodevelopmental delay. Risk of neurodevelopmental delay was defined as no Ages and Stages Questionnaires (ASQ) domain score below threshold (-2 SD) at 2 years of corrected age. The ASQ includes 30 items in 5 neurodevelopmental domains: communication abilities, gross motor skills, fine motor skills, problem solving abilities, and personal-social skills. For each domain, the score obtained by the sum of the items ranges from 0 to 60 and the overall maximum ASQ score is 300 points. For each domain, the score can be categorized using established screening thresholds: an ASQ score <-2 SD below the mean suggests a risk of neurodevelopmental delay in that domai. (NCT01490580)
Timeframe: At 2 years corrected age

InterventionParticipants (Count of Participants)
"Atropine Atracurium Sufentanil as Treated Population"38
"Atropine Propofol as Treated Population"45

[back to top]

Number of Patients With Prolonged Desaturation

"Pulse oxymetry value measured by Masimo technology below 80% for 60 seconds or more.~Duration of intubation is defined by the time between first laryngoscope insertion and last laryngoscope removal after successful intubation. Successful intubation is defined by clear bilateral breath sounds, increasing heart rate and saturation (if previously low) and appropriate flow curves on the ventilator." (NCT01490580)
Timeframe: During intubation procedure, expected duration 1 to 15 minutes

InterventionParticipants (Count of Participants)
Atropine Atracurium Sufentanil54
Atropine Propofol53

[back to top]

Short Term Neurological Outcome: Worsening of Head Ultrasound

Worsening of head ultrasound scans in the 7 days after intubation from the preinclusion evaluation, defined as either a normal scan before inclusion and any grade intraventricular hemorrhage (IVH) afterwards, or as a preinclusion grade 1 or 2 IVH scan deteriorating to grade 3 or 4 IVH, according to Papile's classification; This analysis was not centralized but performed in each center according to its usual protocols. (NCT01490580)
Timeframe: Within 7 days after inclusion

InterventionParticipants (Count of Participants)
Atropine + Propofol14
Atropine + Atracurium + Sufentanil12

[back to top]

Heart Rate

Heart rate recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection (NCT01490580)
Timeframe: from 1 minute before to 60 minutes after the start of premedication

,
Interventionbpm (Mean)
Heart rate from t-1 to t+6, Difference in bpmHeart rate from t-1 to t+9, Difference in bpm
Atropine + Atracurium + Sufentanil11.511.7
Atropine + Propofol3.31.6

[back to top]

Mean Blood Pressure

Blood pressure recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection (NCT01490580)
Timeframe: from 1 minute before to 60 minutes after the start of premedication

,
InterventionDifference in mm Hg (Mean)
Mean arterial blood pressure from t-1 to t+15Mean arterial blood pressure from t-1 to t+30
Atropine + Atracurium + Sufentanil0.2-3.3
Atropine + Propofol-6.8-9.1

[back to top]

Pulse Oxymetry

Pulse oxymetry recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection (NCT01490580)
Timeframe: from 1 minute before to 60 minutes after the start of premedication

,
Intervention% SpO2 (Mean)
SpO2 from t-1 to t+6, Difference in %SpO2 from t-1 to t+9, Difference in %
Atropine + Atracurium + Sufentanil-12.0-15.9
Atropine + Propofol-6.0-8.7

[back to top]

Transcutaneous PCO2 (TcPCO2) Measurement

TcPCO2 recordings 1 minute before the first injection and at 3, 6, 9, 12, 15, 30, 45 and 60 minutes after the first injection (NCT01490580)
Timeframe: from 1 minute before to 60 minutes after the start of premedication

,
InterventionDifference in mm Hg (Mean)
TcPCO2 from t-1 to t+15TcPCO2 from t-1 to t+30
Atropine + Atracurium + Sufentanil14.116.2
Atropine + Propofol8.05.1

[back to top]

Breathing

"In the recovery room the respiratory rate will be measured continuously using the Respir8 respiratory rate monitor. The data will be recorded on the CRF at 15 min intervals.~Breathing rate units are number of breaths as measured in 1 min.~Comparison by t-test: NS between treatments" (NCT01631149)
Timeframe: Measurements will be made during the stay in the recovery room for an average period of 3 hours

Interventionbreaths per min (Mean)
Moderate/Normal Surgical Block14.5
Deep Surgical Block14.5

[back to top]

Nausea and Vomiting

"Using a yes - no questionnaire, the patients will be asked whether they are nauseated or not or whether they vomited. In fact yes indicates the nr of participants.~No statistical analysis was performed." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionparticipants (Number)
Moderate/Normal Surgical Block0
Deep Surgical Block0

[back to top]

Post-operative Pain

"Using a 10 cm visual analogue score pain relief score will be measured. 0 = no pain 10 = most severe pain~No statistical analysis was performed!" (NCT01631149)
Timeframe: measurements are made in the recovery room following surgery for an average prior of 1 hour

Interventionunits on a scale (0-10 cm) (Mean)
Moderate/Normal Surgical Block2.6
Deep Surgical Block2.1

[back to top]

Postoperative Sedation Score

"Using a 5-point sedation scale, sedation levels will be obtained throughout the postoperative period.~0 = wide awake 5= severely sedated, The sedation data were averaged over time." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (0-5) (Mean)
Moderate/Normal Surgical Block2.0
Deep Surgical Block1.3

[back to top]

Surgical Rating Scale

"During the procedure, the surgical condition will be scored by the surgeon using a 5-point surgical rating scale. In order to reduce variability in the surgical rating all surgeries will be performed by one single surgeon. The rating scale will be a 5-point ordinal scale ranging from 1 = poor condition to 5 = optimal surgical conditions. The surgeon will score the condition at 15 minute intervals. In case of a sudden change in surgical conditions additional scores will be added to the case record form. If conditions are poor (score 1 or 2), muscle relaxation will be increased, a score of 1 will be used.~In each subject the scores over time were averaged and a comparison between treatments was performed using a t-test" (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (1-5) (Mean)
Moderate/Normal Surgical Block4
Deep Surgical Block4.7

[back to top]

Incidence of Residual Neuromuscular Blockade

(NCT02109133)
Timeframe: During 24hours after operation

Interventionparticipants (Number)
Moderate Neuromuscular Blockade (Moderate NMB Group)0
Deep Neuromuscular Blockade (Deep NMB Group)0

[back to top]

Maximum Intraocular Pressure During RALRP Under Deep Neuromuscular Blockade

maximum intraocular pressure during RALRP under deep neuromuscular blockade after being positioned in the steep Trendelenburg position with CO2 pneumoperitoneum under deep neuromuscular blockade (NCT02109133)
Timeframe: Maximum intraocular pressure was measured at 60 minutes after CO2 pneumoperitoneum in the ST position

InterventionmmHg (Mean)
Moderate Neuromuscular Blockade (Moderate NMB Group)23.3
Deep Neuromuscular Blockade (Deep NMB Group)19.8

[back to top]

Overall Surgical Condition

overall surgical conditions using the 5-point rating scale as previously described: Grade 5 (optimal), optimal surgical conditions; grade 4 (good), nonoptimal conditions, but an intervention is not required; grade 3 (acceptable), wide surgical view, but an intervention can improve surgical conditions, grade 2 (poor), inadequate conditions, there is a visible view, but an intervention is necessary to ensure acceptable surgical conditions; grade 1 (extremely poor), inability to perform surgery; therefore, intervention is necessary. (NCT02109133)
Timeframe: At the end of the Steep trendelenburg position, an average of 1 hour

Interventionunits on a scale (Median)
Moderate Neuromuscular Blockade4.0
Deep Neuromuscular Blockade3.0

[back to top]

Post-operative Nausea

(NCT02109133)
Timeframe: During 24hours after operation

Interventionevents (Number)
Moderate Neuromuscular Blockade (Moderate NMB Group)4
Deep Neuromuscular Blockade (Deep NMB Group)1

[back to top]

Extubation Time

Awakening time from finished operation to endotracheal extubation. (NCT02174913)
Timeframe: 4 hr

Interventionmin (Mean)
Bispectral Index16.3
Clinical Signs16.6

[back to top]

Total Propofol Dosage

total propofol dosage = propofol dose from start to end of the operation (NCT02174913)
Timeframe: From start anesthesia to finish operation

Interventionmg (Mean)
Bispectral Index2,146
Clinical Signs2,340

[back to top]

Additional Rescue Doses Per Hour Ratio.

Additional Rescue Doses Per Hour Ratio is the number per hour of addition of rescue dose administrated with 10% of initial NMBAs dose. The formula is {(Addition number + 1 / Anesthetic time) x 60}. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

Interventionratio (Mean)
Intubating Dose, Group I1.43455
10% Reduction of Combination of Esmeron® and Nimbex®, Group S1.21014
20% Reduction of Combination of Esmeron® and Nimbex®, Group L0.82128

[back to top]

Anesthetic Time

Time from induction to recovery of anesthesia, asessed up to 3 hours. (NCT02495038)
Timeframe: Intraoperative, an average 4 hours.

InterventionMinute (Mean)
Intubating Dose, Group I163.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S159.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L161.4

[back to top]

Bispectral Index

"The BIS monitor provides a single dimensionless number, which ranges from 0 (equivalent to EEG silence) to 100. A BIS value between 40 and 60 indicates an appropriate level for general anesthesia, as recommended by the manufacturer.~Before induction of anesthesia, bispectral index was measured for baseline. And after injection of NMBAs, bispectral index was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionBIS score (Mean)
Intubating Dose, Group I46.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S46.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L44.3

[back to top]

Body Temperature

"Before induction of anesthesia, body temperature was measured for baseline by oral temperature probe.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min by esophageal temperature probe." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionCelcius degree (Mean)
Intubating Dose, Group I36.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S36.3
20% Reduction of Combination of Esmeron® and Nimbex®, Group L36.3

[back to top]

Duration 25% of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio >25%, assessed up to 2 hours during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 1 hours

InterventionMinute (Mean)
Intubating Dose, Group I51.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S47.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L39.4

[back to top]

Onset of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio=0, assessed up to 15 minutes during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 5 minutes

InterventionSecond (Mean)
Intubating Dose, Group I212.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S230.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L399.3

[back to top]

Operation Time

Time from skin incision to wound dressing assessed up to 8 hours. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

InterventionMinute (Mean)
Intubating Dose, Group I151.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S147.0
20% Reduction of Combination of Esmeron® and Nimbex®, Group L145.9

[back to top]

Peripheral Oxygen Saturation

"Before induction of anesthesia, peripheral oxygen saturation was measured for baseline.~And after injection of NMBAs, peripheral oxygen saturation was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionPercentage (Mean)
Intubating Dose, Group I100
10% Reduction of Combination of Esmeron® and Nimbex®, Group S99.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L100

[back to top]

Recovery Index of Neuromuscular Blocking Agents(NMBAs)

Time from TOF ratio 25% to 75%, assessed up to 1 hour during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 20 minutes

InterventionMinute (Mean)
Intubating Dose, Group I15.9
10% Reduction of Combination of Esmeron® and Nimbex®, Group S16.2
20% Reduction of Combination of Esmeron® and Nimbex®, Group L14.1

[back to top]

Non Invasive Blood Pressure,

"Before induction of anesthesia, non invasive blood pressure was measured for baseline.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

,,
InterventionmmHg (Mean)
Systolic pressureDiastolic pressure
10% Reduction of Combination of Esmeron® and Nimbex®, Group S128.376.7
20% Reduction of Combination of Esmeron® and Nimbex®, Group L128.474.8
Intubating Dose, Group I128.375.6

[back to top]